Baku 2015 medical anti doing and pharmacy guide

Baku 2015 Medical, Anti-doping and Pharmacy Guide

March 2015

WelcomeThe Baku 2015 European Games Operations Committee (BEGOC) Medical and Anti-doping team and the European Olympic Committees (EOC) Medical and Anti-doping Commission welcome you to Baku and the inaugural European Games.

We hope you find this innovative presentation of the guides for medical services, the doping control programme and pharmacy services a useful document.

BEGOC and the EOC Medical and Anti-doping Commission are committed to providing high quality medical care and pharmacy services in keeping with multi-sport summer Games, and an innovative doping control programme under the authority and direction of the EOC, to ensure the integrity of sport is upheld and protect the rights and health of the athletes.

Please view the team as here to help you and work in partnership with you and your colleagues for a successful Games.

Yours sincerely,

Pamela Venning Head of Medical and Anti-doping, BEGOC

James Macleod Director of Athlete Services and Operations, BEGOC

Klaus Steinbach Chairman, EOC Medical and Anti-doping Commission

Baku 2015 European Games4

1. Medical and Anti-doping Organisation for the Baku2015 European Games

1.1 EOC Medical and Anti-doping Commission

1.2 Baku 2015 Medical and Anti-doping team

1.3 NOC Team medical staff meeting

2. Ethical guidelines for healthcare in sports medicine

3. Baku European Games Medical and Anti-doping Operations

3.1 BEGOC Medical and Anti-doping Functional Command Centre

4. Medical encounter system

5. Accreditation


5.2 NOC healthcare professionals

6. Team doctors

6.1 Registration of NOC team doctors

6.2 Bilateral Agreements

6.3 Access and privileges

6.4 Return to play (RTP) decisions

6.5 Malpractice/liability

6.6 Importation and exportation of medicines

6.7 Declaration of medicines and devices on arrival at Villages

6.8 Distribution of medical materials to NOC medical teams

Medical and Anti-doping General Information

Table of Contents

Baku 2015 Medical, Anti-Doping and Pharmacy Guide 5

1. Introduction

2. Medical services in the Villages

2.1 NOC medical services

2.2 Polyclinic services

2.2.1 Dental Services

2.2.2 Ophthalmology Services

2.2.3 Sport Medicine Services

2.2.4 Specialist Services

2.2.5 Athletes Village Square

3. Medical services at competition venues

3.1 Healthcare for athletes, team officials and technical officials

3.2 Healthcare for other client groups

4. Medical services at Independent Training Venues

5. Medical services at other non-competition venues

5.1 Opening and Closing Ceremonies

5.2 Airport

5.3 Media Village

5.4 Games Family hotels

5.5 International Broadcast Centre

6. Designated Games hospitals

7. Repatriation

8. Public health

Medical Services

8.1 Non-smoking policy


Doping Control Programme

European Olympic Committees Overview

1. Governance of the Baku 2015 European Games Anti-Doping Programme

2. Prohibited Substances

3. Medication Use and Therapeutic Use Exemptions (TUEs)

3.1 TUE Application during the Games

4. Whereabouts Information

5. WADA Outreach Programme

6. WADA Independent Observer Programme

European Olympic Committees Technical Procedures for Doping Control by BEGOC for the Baku 2015 European Games

1. Introduction

2. Definitions

3. Notification of Athletes

4. Requirements for Notification of Athletes

5. Preparing for Sample Collection Session

6. Conducting the Sample Collection Session

7. Requirements for Sample Collection

8. Security/post-test administration

9. Transport of Samples and documentation

10. Requirements for Transport and Storage of Samples and Documentation

11. Ownership of Samples


Annex A; Investigating a possible Failure to Comply

Annex B: Modifications for Athletes with Impairments

Annex C: Modifications for Athletes who are Minors

Annex D: Collection of Urine Samples

Annex E: Collection of Blood Samples

Annex F: Urine Samples – insufficient volume

Annex G: Urine Samples that do not meet the requirements for Suitable

Specific Gravity for Analysis

Annex H: Sample Collection Personnel requirements

Appendices

WADA 2015 Prohibited List (external link)

https://wada-main-prod.s3.amazonaws.com/resources/files/wada-2015-prohibited-list-en.pdf


1. Pharmacy Organisation

1.1 Location

1.2 Hours of Operation

1.3 Medicines information Service

2. Prescription Overview

2.1 Prescriptions

3. Medicines available at venues

4. Prescribing and administrating prohibited substances

4.1 Dispensing prohibited medicines from pharmacy

5. The EOC Needle Policy

5.1 Medical justification of injections

6. The Pharmacy Medicines list

6.1 Drug and Prescribing Information

Pharmacy Guide

Medical and Anti-Doping General Information


1. Medical and Anti-doping Organisation for the Baku 2015 European Games

1.1 European Olympic Committees Medical and Anti-doping Commission

Chair:

Prof. Klaus Steinbach EOC Chief Medical Officer IOC Medical Commission member

Members:

Prof. Norbert Bachl IOC Medical Commission Member Professor Sports & Exercise Physiology, University of Vienna

Dr. Emin Ergen Chairman Turkey NOC AnChairman Chairman International Archery Federation Medical & Sport Science Committee

Mr Mark Stuart Pharmacist IOC Medical Commission Member; Games Group WADA Prohibited List Expert Group Member

Dr Jaroslav Vetvicka EOC Medical and Anti-doping Commission member

Dr Christian Shneider Medical Director of the teaching team of the German Olympic Sports Confederation Chairman of the Medical Commission International Federation Bobsleigh and Tobogganing


1.2 Baku 2015 Medical and Anti-doping team

Venue Medical and Anti-doping Managers

Name VenueSevinj Abdiyeva National Stadium and Tofiq Bahramov StadiumFaiq Adullayev Baku Aquatics CentreFariz Akhundov Beach ArenaLala Ahmedova Athletes Village PolyclinicAyla Alasgarova Water Polo Arena & Basketball ArenaRamin Hajiyev Mingachevir, Canoe Sprint Village & BMX VeloparkNargiz Hajiyeva Crystal Hall 1Gunay Ibrahimov Crystal Hall 2 and 3Zarifa Kamilova Mountain Bike Velopark and Baku Shooting CentreSevda Karimova Heydar Aliyev ArenaMehriban Mammadova National Gymnastics Arena and Baku Sports HallNarmina Rzayeva Games Family Hotel, Media Village and

International Broadcast Centre

Denis Shabanov Bilgah Beach and Freedom Square


1.3 NOC Team medical staff meeting

BEGOC Medical and Anti-doping and the EOC Medical and Anti-doping Commission invite NOC team physicians and medical personnel to a meeting in the Chefs de Mission Meeting Hall on 11 June at 16:30.

2. Ethical guidelines for healthcare in sportsmedicine The European Olympic Committees Medical and Anti-doping Commission (EOC MC) and the BEGOC Medical Services team are committed to the Olympic Movement Medical Code in order to ensure that all athletes receive optimal care from all clinicians at the Baku 2015 European Games. The Olympic Movement Medical Code is available online at

www.olympic.org/PageFiles/61597/Olympic_Movement_Medical_Code_eng.pdf

3. Baku European Games Medical and Anti-dopingOperations

3.1 BEGOC Medical and Anti-doping Functional Command Centre

Medical and Anti-doping services will be coordinated through a Functional Command Centre (FCC) located within BEGOC’s Games Headquarters (GHQ) in Baku.

The FCC will:

• Maintain a constant network of communication with all venues across Baku and Azerbaijan (competition venues, independent training venues, non-competition venues and polyclinics).

• Coordinate staffing, logistics, administration and resource management forthe medical and doping control programme, including public health matters.

www.olympic.org/PageFiles/61597/Olympic_Movement_Medical_Code_eng.pdf


• Monitor medical activity across all medical services, and resolve both escalated issues and NOC-related issues.

• Coordinate the collection, management of documentation and transfer of samples for the doping control programme.

• Report directly to the Games Operations Centre (GOC), the EOC Chief Medical Officer, and communicate as needed to NOC Chief Medical Officers, either directly or through NOC Services and Relations.

• Assist in the coordination of emergency responses.

• Maintain communications and networks with Azerbaijan external agencies, such as the Ministry of Health (including public health), the designated Games hospitals, the ambulance service and the Ministry of Emergency Situations (Health).

4. Medical encounter systemAll venues will use a secure, electronic medical encounter system. Data will be entered by BEGOC Medical Services workforce at terminals located at athlete medical stations, polyclinics, the Games Family hotel, the International Broadcast Centre (IBC) and the Media Village. Data and statistics will be collated at the Medical FCC and will be used to compile daily reports for the EOC Chief Medical and Anti-doping Commission Chairman and general reporting.

The electronic medical encounter system is an integral part of Games management. Patients who consult with the BEGOC clinical team at Games facilities, as well as applicable NOC healthcare personnel, are requested to help BEGOC clinical teams to complete these records (electronic or paper) in order to ensure continuity of care.


5. Accreditation


The EOC Medical and Anti-doping Commission members will be accredited in the B category, in accordance with the European Games Accreditation Manual. This will allow access to all zones, including the residential zones of the Villages.

5.2 NOC healthcare professionals

NOC healthcare professionals will be accredited in the Ao category, in accordance with the European Games Accreditation Manual. NOC healthcare professionals may have access to the field of play and to athlete preparation areas, and will also have access to back-of-house administration organisation areas if they contain treatment facilities.

6. Team doctors

6.1 Registration of NOC team doctors

A special registration process for NOC team doctors is in place for the Baku 2015 European Games. Team doctors must be registered with the Republic of Azerbaijan Ministry of Health to practice during the Games operational period. This temporary, special-purpose registration will license doctors to treat only members of their own team and will permit doctors to prescribe and order imaging and pathology tests at the Athletes Village Polyclinic and the Canoe Sprint Village Polyclinic.

All NOC team doctors must be registered by 25 April 2015.

6.2 Bilateral Agreements

Where NOC medical staff wish to treat members from other delegations, a bilateral agreement is required. The form for this agreement is on the e-Qəzet. This form must be submitted to NOC services by 25 April 2015.


6.3 Access and privileges

During the Games, NOC team doctors will be able to:

• Request physiotherapy and other treatments at venues and at the Athletes Village and Canoe Sprint Village Polyclinics.

• Request diagnostic imaging (MRI, CT, ultrasound and X-ray) and laboratory tests at the Athletes Village Polyclinic and at the Canoe Sprint VillagePolyclinic.

• Write prescriptions for members of its own delegation, to be dispensed at the Athletes Village Pharmacy and Canoe Sprint Village Polyclinic (free of charge) or at any commercial pharmacy (where a fee will be payable). For details of the medicines available from the polyclinic pharmacies, pleaserefer to the Pharmacy section in this guide.

• Registered and accredited team doctors will be able to accompany athletesand members of their delegation to hospital and, with the consent of the patient, discuss the examination and treatment with the admittingphysician. Final decisions and responsibility will rest with the admitting physician or surgeon.

• Team doctors who fail to register will not be entitled to any of the above privileges other than accompanying members of their delegation to hospital.

6.4 Return to play (RTP) decisions

Clinical staff are available to advise on an athlete’s fitness to return to play (RTP). However, the final decision will rest with the NOC physician. If there is a difference in clinical opinion between the BEGOC clinical team and the NOC physician, the final decision rests with the EOC MC. The International Federation (IF) or European Federation (EF) medical officer may be consulted if required. BEGOC Medical Services personnel will not normally be able to make the final RTP decision. In the event of head injury or a life-threatening condition, the final decision on how to proceed will rest with the BEGOC medical team.


6.5 Malpractice/liability

BEGOC assumes no responsibility for any healthcare provided to NOC team members and delegates by NOC healthcare personnel. BEGOC will not provide malpractice or liability insurance for NOC healthcare personnel; it is the responsibility of each NOC to ensure malpractice/liability insurance is in place. However, it is recommended that team doctors inform their medical defence organisation that they are travelling abroad with a sports team and check they are covered for this role. Except for Good Samaritan acts, team doctors should not treat any Azerbaijan citizens unless they are fully registered with the Republic of Azerbaijan Ministry of Health.

6.6 Importation and exportation of medicines

The Baku 2015 Customs and Freight Guide contains full guidance on the importation and exportation of medicines for team or personal use, including the specific requirements for controlled drugs.

6.7 Declaration of medicines and devices on arrival at Villages

The list of medicines, pharmaceutical products or medical devices that the team is bringing into Azerbaijan must also be declared to the Baku 2015 Medical Services by the NOC Chief Medical Officer or the designated head doctor accompanying a team.

The declaration should be emailed to [email protected] by 17 April 2015. The template can be found in the Customs and Freight Guide. It must be completed in English, or accompanied by an English translation.

This list constitutes a statement on behalf of the NOC and will be kept by Baku 2015 Medical Services and will be shared with the Republic of Azerbaijan Ministry of Health, Customs or security agencies if requested.

In exceptional circumstances the list may be provided to the Polyclinic Pharmacy within 24 hours of entry of the medicines into the Athlete Village.

mailto:[email protected]


Prescription pads will only be issued to NOC team doctors after the list has been submitted on behalf of the NOC.

See below for an overview and guidance on importing pharmacy products for personal use into Azerbaijan.

The head doctor accompanying a team will need to provide a list of the medicines, pharmaceutical products (including dietary supplements) and devices the team are bringing into Azerbaijan, including dosages and amounts. Details of the information that must be included on this list are included in the Pharmacy section of this guide. The list will constitute a statement on behalf of the NOC and will be kept by BEGOC Medical Services. The list should be sent to [email protected] by 17 April 2015.

For medicines not licensed in Azerbaijan, it is advisable (in case any complications arise) that an acceptable, Azerbaijan-licensed alternative should be prescribed if available. Please contact [email protected] if you have any queries.

Any medicines will need to be taken out of Azerbaijan on departure or at the end of the Games. No export licences or documentation will be required unless the medicines are controlled drugs and the quantity constitutes more than three months’ supply. For a more in-depth explanation of the rules governing the import and export of medicines and medical devices for human use, please refer to the Baku 2015 European Games Customs and Freight Guide on the e-Qəzet. A sample form for the list of items is also available.

For the definitive list of medicines available from the polyclinic pharmacies, along with comprehensive prescribing information for each drug, please refer to the Pharmacy section of this guide.




6.8 Distribution of medical materials to NOC medical teams

Hard copies of the Baku 2015 European Games Medical, Anti-doping and Pharmacy Guide will be distributed to NOC medical teams at Games time during the BEGOC Medical team and EOC Medical and Anti-doping Commission meeting on 11 June 2015. In addition, the following materials will be distributed to team doctors upon arrival in the Athletes Village, on production of their letter confirming registration with the Republic of Azerbaijan Ministry of Health:

• imaging requisition forms

• laboratory requisition forms

• prescription pads

• specialist consultation forms

Medical Services


1. IntroductionThe Baku 2015 European Games Operations Committee (BEGOC) has developed a comprehensive healthcare programme for the inaugural European Games. This programme has been designed to meet the healthcare needs of athletes, team officials, technical officials, the European Games Family, members of the media, workforce and spectators. During the Games period, medical services will be delivered by teams of clinical professionals at facilities equipped and designed to deliver immediate and necessary care to all client groups.

2. Medical services in the Villages2.1 NOC medical services

BEGOC will provide a certain number and variety of furnishings for NOCs’ medical spaces. The quantities will be distributed across each NOC’s allocated medical rooms according to the size of the delegation, in accordance with the numbers given below. Other useful guest items (for example, blankets and pillows) may be requested from the resident centres in the Villages.

Number of items based on delegation size:

NOC Delegation size NOC Medical Space1–74 2 (15m²)75–149 3 (15m²)150–224 3 (15m²)225–299 4 (15m²)300–374 5 (15m²)375+ 5 (15m²)

2.2 Polyclinic services

The polyclinic at the Athletes Village will be open and offer a reduced service between 3 June and 7 June from 08:00 to 20:00 daily. From 8 June to 30 June 2015, services will be available from 07:00 to 23:00 with a 24 hour emergency service. On 1 July there will be no sport specific services available. All services will close at 18:00 on 1 July.


Services at the Canoe Sprint Village will be offered from 10 June to 18 June. Services will be available from 07:00 to 23:00 daily with an on call service overnight. The service will end at 18:00 on 18 June.

An ambulance will be on site 24 hours a day for the operational period of the Games at both Villages. The polyclinics will have the following services available, or will have access to services as follows:

Medical Services Athletes Village Canoe Sprint VillageDental Yes Local Services Emergency services Yes Yes

Imaging (Ultrasound) Yes YesImaging (X-Ray, MRI, CT) Local Services Local ServicesLaboratory services Yes Local Services

Ophthalmology(Acute

services)

Yes Local Services

Pharmacy Yes Local Services Physiotherapy Yes YesFamily Practice Yes YesSpecialist clinics Yes Local Services

Sports medicine Yes Yes

2.2.1 Dental Services

The BEGOC Dental Service will provide immediate and necessary dental care for athletes and team officials and members of the European Games Family during the Games operational period. However, depending on the seriousness of the case, patients may be referred to Hospital (referrals will be free of charge).

2.2.2 Ophthalmology Services

The BEGOC Ophthalmology Service will provide immediate and necessary


treatment for athletes and team officials and members of the European Games Family during the Games operational period. Eyesight testing will be free of charge. Replacement glasses and contact lenses will be available for those members of the Games Family competing or adjudicating in sport. However, depending on the seriousness of the case, patients may be referred to hospital.

2.2.3 Sport Medicine Services

The following sport medicine services will be provided at the Athletes Village Polyclinic:

• Physiotherapy

• Sport medicine doctors

• Radiology consulting and ultrasound

• Osteopathy

• Chiropractic

• Sport massage therapy

• Podiatry

A booking system will be used for sport medicine with open access sessions available. Priority will be given to athletes. Ice bathes will be available via a booking system at the polyclinic. These must be managed by a member of the NOC delegation and the NOC is totally responsible for the athletes using these ice baths.

The following sport medicine services will not be provided by BEGOC but may be available in Baku at the NOC’s own cost:

• Antigravity/underwater treadmills

• X-ray/CT guided injections

• Orthotic prescription

• Isokinetic dynamometry


2.2.4 Specialist Services

Specialist services e.g. cardiology and dermatology will be available as required.

2.2.5 Athletes Village - Village Square

First aid services will be provided in the Village Square as required.

3. Medical services at competition venuesThese services will be supported by services at the polyclinics and the designated Games hospitals. Medical services in each competition venue will be managed by the Venue Medical and Anti-doping Manager. BEGOC’s Medical Services teams at each venue will work in line with the IF, EF and EOC rules for the sport.

3.1 Healthcare for Athletes, Team Officials and Technical OfficialsHealthcare for athletes, team officials and technical officials (international and national) will be provided at athlete medical stations, which are generally located close to the field of play. Physiotherapists will treat athletes and the crowd doctor will be called to treat team officials and technical officials, or a member of the field of play team can assist if convenient. Medical services will be available from one hour before the start of training, warm up or competition until one hour after training, warm up or competition ends. However, times vary in some venues.

The following services will be provided:

• Athlete-dedicated ambulance services

• Dental services (Boxing and Water Polo competition venues only)

• Field of play recovery teams

• Physiotherapy

• Sport medicine advice from the Athletes Village Polyclinic


For athletes who choose to stay outside the Villages, there will be no medical services in their accommodation.

3.2 Healthcare for other client groups

Members of the European Games Family (EGF), press and broadcast, sponsors, workforce and spectators will be treated by the closest accessible spectator medical team to them in the venue.

National Technical Officials (NTOs) and International Technical Officials (ITOs) will access medical services through the normal accommodation provision. NTOs and ITOs will be able to access some services in the Athletes Village Polyclinic or the local services in Mingachevir. Access to these services will be by appointment.

Any member of the EGF, NTOs, ITOs, press or broadcast requiring hospital admission will be taken to one of the two designated Games hospitals in Baku or the Central Hospital in Mingachevir.

4. Medical Services at Independent Training Venues Limited medical services will be provided for athletes at independent training venues. Depending on IF or EF rules, the following services will be available:

• ambulances (specific sports)

• emergency care physicians (specific sports)

• physiotherapists

These services will only be available if athletes are training.


5. Medical services at other non-competition venues

5.1 Opening and Closing Ceremonies

Medical services will be provided to all groups at the Opening and Closing Ceremonies, and will be tailored to the different groups and their needs. Ambulances will support this response.

5.2 Airport

The Heydar Aliyev International Airport has an experienced medical team who regularly liaise with the public ambulance service for transfer to a designated Games hospital. These arrangements will continue for the Games operational period.

5.3 Media Village

A family-practice service will be available at the Media Village from 07:00 to 23:30. An ambulance will be available 24 hours a day.

5.4 Games Family Hotels

A family-practice service will be available from 07:00 to 23:00 at the main Games Family Hotel, the Fairmont Baku. An on-call service will be available from 23:00 to 07:00. An ambulance will be on site 24 hours a day. In the event of an emergency, members of the EGF would be transferred to either Hospital Number 1, the Baku Health Centre or the appropriate hospital in a specified care pathway.

5.5 International Broadcast Centre

A family-practice service will be available at the International Broadcast Centre (IBC) from 06:00 to 23:00. Two first aiders will support the doctor in the IBC. An ambulance will be available 24 hours a day.


6. Designated Games hospitals Hospital care is free during the operational period of the European Games (8 June to 1 July 2015). Games Family delegates should ensure they have healthcare insurance outside these dates. The hospitals are located on the Games Route Network (GRN).

The designated Games hospitals are as follows:

Baku

• Hospital Number 1

• Baku Health Centre

Mingachevir

• Central Hospital

7. Repatriation BEGOC will provide a repatriation service during Games time. The service will include the cost of bringing a relative to Baku and accompanying medical personnel. In the event of a death, the repatriation process will cover the cost of transporting the body. All arrangements will be managed by BEGOC.

8. Public health Azerbaijan has a public health surveillance and response system, which is managed by the Republic of Azerbaijan Ministry of Health Public Health Department.

Team doctors will be asked to participate in the following syndromic surveillance and report to the Polyclinic Manager any cases or suspected cases


with the following symptoms/conditions:

• diarrhoea and vomiting

• fever

• jaundice

• meningitis/encephalitis

• rash

• respiratory symptoms

If any of these symptoms are severe, the team doctor should bring the team member to the Polyclinic to ensure there is compliance with Azerbaijan legislation on communicable disease surveillance.

Food quality monitoring will be managed by BEGOC’s Catering, Cleaning and Waste team. It is advisable that teams drink bottled water in Azerbaijan.

8.1 Non-smoking policy

Smoking will not be permitted in the following areas:

• the field of play at all venues

• seating bowls at all venues (including training venues)

• enclosed bars or restaurants at all venues

• anywhere in any of the Villages, including bedrooms and living quarters, except in designated smoking areas (see below)

• enclosed staff break areas

• Games transport vehicles

• sponsor hospitality areas

In all venues, smokers will be directed to discrete, designated and clearly signposted smoking areas away from the main public/workforce domains,


which will have stub bins for cigarettes and will be regularly cleaned. Smoking close to the perimeters of venues will be discouraged. In line with public health advice and for the avoidance of doubt, e-cigarettes and other smoking stimulators may not be used in the areas other than the dedicated smoking areas.

Doping Control Guide


European Olympic Committees Overview

1. Governance of the Baku 2015 European GamesAnti-Doping ProgrammeThe European Olympic Committees (EOC) is responsible for the Baku 2015 European Games (the Games) Anti-Doping Programme, including In-Competition and Out-of-Competition testing from the opening of the Athletes Village and Canoe Sprint Village (the Villages) on 8 June 2015 up to, and including, the day of the Closing Ceremony on 28 June 2015 (the Games Period).

The EOC is a signatory to the World Anti-Doping Code (the Code). The EOC has established the EOC Anti-Doping Rules (the EOC Rules) in compliance with the general principles of the Code. The EOC Rules are complemented by the WADA International Standards, and outline the various Anti-Doping Rule Violations (ADRVs) and the detailed results management process following a possible ADRV. The EOC Rules shall apply to the Games, from the date of the opening of the Villages on 8 June 2015 to the Closing Ceremony of the Games on 28 June 2015. Athletes entered at the Games may be tested by the EOC during the entire period, as described above, regardless of their location. All Participants (Athletes and Athlete Support Personnel) accept the EOC Rules as a condition of participation and are presumed to have agreed to comply with the EOC Rules, which agreement is also confirmed when signing the Eligibility Conditions Form. All National Olympic Committees (NOCs) and European and International Federations (EFs/IFs) shall have formally declared their acceptance of the EOC Rules through the submission of a signed declaration form to the EOC. Any NOC or EF/IF that has not accepted the EOC Rules shall be deemed ineligible to participate in the Games.

The EOC Medical and Anti-Doping Commission is responsible for all anti-doping regulations applicable to the Games, including the EOC Rules. The EOC Medical and Anti-Doping Commission is responsible for the regulations related to Therapeutic Use Exemptions (TUE) as outlined in the EOC Rules. Unless specifically directed in the EOC Rules, the person responsible for the administration of the provisions thereof is the Chairman of the EOC Medical and Anti-doping Commission.


The Baku 2015 European Games Operations Committee (BEGOC) is responsible for the implementation of the Games Doping Control Programme, which includes the infrastructure and operational provisions to enable doping control testing as well as analysis of the doping control Samples to be conducted in accordance with the EOC Rules. To assist with the planning, management and implementation of the Doping Control Programme, BEGOC has appointed PWC Global Service GmbH & Co. KG as the Doping Control Supplier.

BEGOC recognises the need to ensure that anti-doping operations are carried out in conformity with the International Standard for Testing and Investigations (ISTI), and confirms its support in assisting the EOC to fulfil its role and responsibilities under the Code. In particular, it is the primary objective of the BEGOC Medical and Anti-Doping function to ensure the safety and security of both the athletes and the doping control Samples through the entire doping control process.

Samples collected by the BEGOC Medical and Anti-Doping function will be analysed at a WADA-accredited Laboratory and will include both urine and blood tests. The results of the tests will be provided to the EOC Medical and Anti-Doping Commission Chairperson and WADA directly from the Laboratory. Generally, negative results will be provided within 24 hours of the samples arriving at the Laboratory and it is expected that results from Adverse Analytical Findings will be provided within 48 hours, with the exception of the EPO test results, which will be provided within 72 hours.

In compliance with the Code and the WADA International Standards, Samples may be subject to further analysis subsequent to the Closing Ceremony. Any ADRV discovered as a result thereof shall be dealt with in accordance with the EOC Rules.

2. Prohibited substancesThe WADA 2015 Prohibited List lists the substances and methods prohibited for the Baku 2015 European Games. If, at the time of the Games, the 2015 Prohibited List is amended, the valid version that can be retrieved from the WADA website (www.wada-ama.org) is the applicable one.

www.wada-ama.org


All athletes and athlete support personnel need to familiarise themselves with the 2015 Prohibited List.

3. Medication use and Therapeutic UseExemptions (TUE) It is the responsibility of the athlete to determine whether a substance he/she is using or considering using is prohibited. NOCs are encouraged to be proactive in assisting their athletes to identify what substances they may wish to use, to identify what the therapeutic use alternatives are, if appropriate, and to submit forms in a timely and legible manner to the relevant Anti-Doping Organisation (ADO) in case of the use of an otherwise prohibited substance. All Participants, NOCs, IFs and EFs are strongly advised to refer to Article 4.4 of the EOC Rules, which sets out the provisions regarding TUEs.

At all times, athletes are strongly advised to check the status of the medications they are using or considering using with their team doctors. If, during the Games, further clarification is required, the athlete should check with the NOC Medical Officer(s) or a member of the EOC Medical and Anti-Doping Commission.

All athletes competing at the Games who seek a TUE are expected to have applied to the relevant EF/IF in accordance with the applicable rules of the EF/IF so that the TUE is granted no later 7 June 2015, the day before the opening of the Athletes Village. The notification requirements in Article 4.4.3 of the EOC Rules should then be complied with. The EOC will recognise TUEs issued in compliance with the Code by other EFs, IFs and ADOs.

Athletes who do not have a TUE may apply to obtain a TUE from the EOC Medical and Anti-Doping Commission at least 30 days before the Games. TUE applications can be emailed to [email protected]. In cases of emergency or exceptional circumstances, a TUE can be applied for during the course of the Games.

The in-competition period for the European Games in Baku will be from the opening of the Athlete Village on 8 June 2015 until the Closing Ceremony on 28 June 2015.



For all athletes competing in the Games, the EOC will require the respective NOC to have a copy of the TUE Certificate available for the duration of the Games. All TUEs should be submitted through the ADAMS system prior to the Games. If the TUE authorisation is not available on ADAMS, copies of the TUE Certificates should be submitted to the EOC Medical and Anti-doping Commission by 8 May 2015 via the email [email protected] or be handed in upon arrival of the delegation at either the Athletes Village or Canoe Sprint Village Polyclinic Pharmacy, where there will be a secure box.

TUEs granted after 8 May 2015 must still be submitted to [email protected] or be given to the EOC Medical and Anti-Doping Commission on arrival in the Athletes Village. TUE Certificates or new applications can be submitted to the EOC Medical and Anti-Doping Commission via the Pharmacy in the Athletes Village Polyclinic or the Canoe Sprint Village Polyclinic.

The details of the TUE process, including the TUE application process, the medical documentation in support of the application needed, and the criteria for granting a TUE are outlined in the EOC Rules and the International Standard for TUEs. The decisions of the EOC Medical and Anti-Doping Commission will be conveyed to the athlete’s NOC and the EF/IF, and reported to WADA.

The EOC Medical and Anti-doping Commission will consider a retroactive TUE application for a prohibited substance and/or method used during the Games if the prohibited substance and/or method was used in an emergency situation, or treatment of an acute medical condition was necessary.

3.1 TUE application during the Games

For TUE applications during the Games, the completed TUE forms must be given to the EOC Medical and Anti-doping Commission Therapeutic Use Exemption Committee (TUEC). They can be emailed to [email protected] or deposited in the TUE submission box at the Pharmacy in the Athletes Village Polyclinic.

A TUE application should normally be submitted to the TUEC before treatment, but this may be expedited by directly contacting the Chair of the TUEC to obtain a verbal notification and a TUE. A written TUE application will subsequently need to be submitted.





TUE forms are available from the pharmacy in the Athletes Village and Canoe Sprint Polyclinic.

4. Whereabouts Information The EOC, as a Signatory to the World Anti-Doping Code, and BEGOC recognise that an effective Out-of-Competition testing programme is essential to the fight against doping in sport. They also recognise that effective Out-of-Competition testing depends upon accurate and complete Athlete Whereabouts information.

The ultimate responsibility for providing Whereabouts information rests with each athlete; however, it will be the responsibility of each NOC to obtain whereabouts of athletes staying in Azerbaijan (from the date of arrival to the date of departure).

The EOC therefore requests that all NOCs:

• ensure that Athletes who are included in an International Federation (IF) or National Anti-Doping Organisation (NADO) Registered Testing Pool (RTP) comply with their obligations and make their Whereabouts information for the 1st European Games period available to the EOC; and

• for athletes not included in an IF or NADO RTP, provide information to the EOC regarding accommodation arrangements (rooming lists in the Villages, or alternative address for Athletes not residing in the Villages), no later than 24 hours after the Delegation Registration Process (DRP) is complete. This information should be submitted using a template provided by the EOC, and sent to an email address that will be communicated to the NOC prior to the Games; and

• ensure that arrival and departure information is submitted to the BEGOC ADS system in a timely manner and is accurate and up-to-date for all athletes participating at the European Games.

The EOC will refer to the BEGOC ADS system for arrival and departure information and to the BEGOC Sport Information Centre at the Athletes Village for athlete training information.


These components are of paramount importance to enable locating athletes for testing in the lead-up to the competition period. In the event that the information received from the NOCs is incomplete, or when NOCs refrain from updating or sharing the information with the EOC and BEGOC, the EOC has the right to ask the NOC for more detailed Whereabouts information.

5. WADA Outreach Program

The WADA Outreach Program was developed to inform and unite both athletes and their entourage about anti-doping and the “Say NO! to Doping” message. WADA will set up its Athlete Outreach Centre in the Main Dining Hall of the Athletes Village. Athletes are encouraged to visit the Centre when, and as often, it is most convenient for them so that they feel comfortable asking questions about anti-doping issues. Staffed by anti-doping experts and retired athletes recruited from around the world, the Athlete Outreach Program format allows athletes to ask their anti-doping questions of peers and experts, enforcing the quality and credibility of the anti-doping message. WADA’s print material, such as the Athlete Guide and the Prohibited List, (available in multiple languages), also provides important information about the athlete’s responsibilities under the World Anti-Doping Code and the consequences of doping.

6. WADA Independent Observer Program The intent of the WADA Independent Observer (IO) Program is to assist the EOC and BEGOC in achieving a higher standard in the way their Code-compliant rules are implemented and their anti-doping programmes are conducted.

A WADA IO team will observe the doping control and results management processes during the Games, will liaise with the EOC and BEGOC on a regular basis to provide feedback on the observations to amend operations and procedures wherever needed and, following the Games, will provide a summary of observations and recommendations for future programmes relating to the conduct of the doping control procedures.


European Olympic Committees Technical Procedures for Doping Control by BEGOC for the Baku 2015 European Games

1. IntroductionThe European Olympic Committee’s (EOC) Anti-Doping Programme for the Baku 2015 European Games complies with the World Anti-Doping Code (the Code) and the mandatory International Standards that comprise the World Anti-Doping Programme.

As set out in the EOC Rules, “The EOC is solely responsible for the initiation and direction of testing during the European Games. The Organising Committee for the European Games is responsible for all Doping Control Requirements and Financial Costs. Doping Control procedures will be undertaken in conformance with the EOC, IOC and WADA rules.”BEGOC has therefore prepared this Doping Control Guide in conformity with the following sections of the World Anti-Doping Code’s mandatory International Standard for Testing and Investigations (ISTI):

• Notification of Athletes;

• Preparing for the Sample Collection Session;

• Conducting the Sample Collection Session;

• Security/post-test administration;

• Transport of Samples and documentation;

• Ownership of Samples;

• Annex A: Investigating a Possible Failure to Comply;

• Annex B: Modifications for Athletes with Impairments;

• Annex C: Modifications for Athletes who are Minors;


• Annex D: Collection of Urine Samples;

• Annex E: Collection of Blood Samples;

• Annex F: Urine Samples – Insufficient Volume;

• Annex G: Urine Samples that do not meet the requirement for Suitable Specific Gravity for Analysis;

• Annex H: Sample Collection Personnel requirements.

These Technical Procedures for Doping Control outline BEGOC’s implementation of the aforementioned areas of the WADA ISTI.

These Technical Procedures for Doping Control do not address the requirements within the ISTI relating to Section 4 – Planning effective Testing, Section 11 – Gathering, assessment and use of intelligence or Section 12 – investigations. These requirements are the sole responsibility of the EOC.

BEGOC shall carry out Doping Control in accordance with these Technical Procedures for Doping Control on behalf of the EOC at Baku 2015 European Games venues only.

In implementing these Technical Procedures for Doping Control, BEGOC complies with the WADA International Standard on the Protection of Privacy and Personal Information.

As part of the EOC Anti-Doping Programme, the purpose of these Technical Procedures for Doping Control is to plan for effective Testing and to maintain the integrity and identity of the Samples collected, from the point the Athlete is notified of the test to the point the Samples are transported to the laboratory for analysis.

2. Definitions Unless defined in the EOC Anti-Doping Rules, the definitions of the Code and the International Standards apply, mutatis mutandis, to the capitalised terms appearing throughout these Technical Procedures.


3. Notification of Athletes

3.1 Objective

To ensure that an Athlete who has been selected for Testing is properly notified of Sample collection as outlined in Procedure 4.1, that the rights of the Athlete are maintained, that there are no opportunities to manipulate the Sample to be provided, and the notification is documented.

3.2 General

Notification of Athletes starts when BEGOC initiates the notification of the selected Athlete and ends when the Athlete arrives at the Doping Control Station or when the Athlete’s possible Failure to Comply is brought to the attention of the EOC. The main activities are;

a) Appointing Venue Medical Managers (VMMs), Lead Doping Control Officers (Lead DCOs), Doping Control Officers (DCOs), Chaperones and other Sample Collection Personnel;

b) Locating the Athlete and confirming his/her identity;

c) Informing the Athlete that he/she has been selected to provide a Sample and of his/her rights and responsibilities;

d) For No Advance Notice Sample collection, continuously chaperoning the Athlete from the time of notification to the arrival at the designated Doping Control Station; and

e) Documenting the notification, or notification attempts.

3.3 Requirements prior to notification of Athletes

3.3.1 Save in exceptional and justifiable circumstances, No Advance notice Testing shall be the method for Sample collection.

3.3.2 To conduct or assist with Sample Collection Sessions, BEGOC shall appoint and authorise Sample Collection Personnel who have been trained


for their assigned responsibilities, who do not have a conflict of interest in the outcome of the Sample collection, and who are not Minors.

3.3.3 A DCO’s/Chaperone’s Games-time accreditation shall be the official identification that is provided and controlled by BEGOC.

3.3.4 BEGOC has established criteria to validate the identity of an Athlete selected to provide a Sample. This ensures the selected Athlete is the Athlete who is notified. Identification will typically be done through the Athlete’s Games-time accreditation or through an alternative reliable piece of photo identification. The method of identification of the Athlete shall be documented on the Doping Control documentation.

3.3.5 BEGOC or the DCO/Chaperone, as applicable, shall establish the location of the selected Athlete and plan the approach and timing of notification, respectfully taking into consideration the specific circumstances of the sport/competition/training session and the situation in question.

3.3.6 BEGOC shall ensure that reasonable attempts are made to notify Athletes of their selection for Sample collection. BEGOC shall record in detail Athlete notification attempt(s) and outcome(s).

3.3.7 The Athlete shall be the first one notified that he/she has been selected for Sample collection except where prior contact with a third party is required as specified in Procedure 3.3.8.

3.3.8 BEGOC or the Lead DCO/DCO/Chaperone, as applicable, shall consider whether a third party is required to be notified prior to notification of the Athlete. This may include situations where the Athlete is a Minor as provided for in Annex C: Modifications for Athletes who are Minors, where required by an Athlete’s impairment as provided for in Annex B: Modifications for Athletes with Impairments, or in situations where an interpreter is required and available for the notification.


4. Requirements for notification of Athletes 4.1 When initial contact is made, BEGOC, Lead DCO, DCO or Chaperone, as applicable, shall ensure that the Athlete and/or a third party, if required, is informed:

a) That the Athlete is required to undergo a Sample collection;

b) That the Sample collection is being conducted under the authority of the EOC;

c) Of the type of Sample collection and any conditions that need to be adhered to prior to the Sample collection;

d) Of the Athlete’s rights, including the right to:

i. Have a representative and, if available, an interpreter accompany him/her;

ii. Ask for additional information about the Sample collection process;

iii. Request a delay in reporting to the Doping Control Station for valid reasons; and

iv. Request modifications as provided for in Annex B: Modifications for Athletes with Impairments.

e) Of the Athlete’s responsibilities, including the requirement to:

i. Remain within direct observation of the DCO/Chaperone at all times from the point initial contact is made by the DCO/ Chaperone until the completion of the Sample collection procedure;

ii. Produce identification;

iii. Comply with Sample collection procedures (and advised of the possible consequences of Failure to Comply); and


iv. Report immediately for Sample collection, unless there are valid reasons for delay.

f) Of the location of the Doping Control Station;

g) That should the Athlete choose to consume food or fluids prior to providing a Sample, he/she does so at his/her own risk;

h) That the Athlete should avoid excessive rehydration, having in mind the requirement to produce a Sample with a Suitable Specific Gravity for Analysis; and

i) That the urine Sample provided by the Athlete to the DCO should be the first urine passed by the Athlete subsequent to notification, i.e. he/she should not pass urine in the shower or otherwise prior to providing a Sample to the DCO.

4.2 When in-person contact is made, the DCO/Chaperone shall:

a) From the time of such contact until the Athlete leaves the Doping Control Station at the end of his/her Sample Collection Session, keep the Athlete under observation at all times;

b) Identify themselves to the Athlete using their official BEGOC identification;

c) Confirm the Athlete’s identity. Any inability to confirm the identity of the Athlete shall be documented and reported to the EOC. In such cases, the DCO responsible for conducting the Sample Collection Session shall decide whether it is appropriate to report the situation in accordance with Annex A: Investigating a Possible Failure to Comply.

4.3 The DCO/Chaperone shall have the Athlete sign Doping Control documentation to acknowledge and accept the notification. If the Athlete refuses to sign that he/she has been notified or evades the notification, the DCO/Chaperone shall, if possible, inform the Athlete of the consequences of a Failure to Comply if possible, and the Chaperone (if not the DCO) shall immediately report all relevant facts to the DCO. When possible the DCO shall continue to collect a Sample. The DCO shall document the facts and report the circumstances to BEGOC and the EOC as soon as possible. The EOC shall follow the steps prescribed in Annex A: Investigating a Possible Failure to Comply.


4.4 The Lead DCO/DCO/Chaperone may at their discretion consider any valid third party requirement or any valid request by the Athlete for permission to delay reporting to the Doping Control Station following acknowledgement and acceptance of notification, and/or to leave the Doping Control Station temporarily after arrival, and may grant such permission if the Athlete can be continuously chaperoned and kept under direct observation during the delay and if the request relates to the following activities:

a) For In-Competition Testing:

i. Participation in a Medal Ceremony;

ii. Fulfilment of media commitments;

iii. Competing in further Competitions;

iv. Performing a warm down;

v. Obtaining necessary medical treatment;

vi. Locating a representative and/or interpreter;

vii. Obtaining photo identification; or

viii. Any other reasonable circumstances, as determined by the DCO, taking into account any instructions of the EOC.

a) For Out-of-Competition Testing:

i. locating a representative and/or an interpreter;

ii. completing a training session;

iii. receiving necessary medical treatment;

iv. obtaining photo identification; or

v. Any other reasonable circumstances, as determined by the DCO, taking into account any instructions of the EOC.


4.5 The DCO or other authorised Sample Collection Personnel shall document the reasons for a delay in reporting to the Doping Control Station and/or reasons for leaving the Doping Control Station that may require further investigation by the EOC. Any failure by the Athlete to remain under constant observation should be recorded.

4.6 A Lead DCO/DCO/Chaperone shall reject a request for delay from an Athlete if it will not be possible for the Athlete to be continuously observed during such a delay.

4.7 If the Athlete delays reporting to the Doping Control Station other than in accordance with Procedure 4.4 but arrives prior to the Lead DCO/DCOs departure, the Lead DCO/DCO shall decide whether to process a possible Failure to Comply. If at all possible the Lead DCO/DCO shall proceed with collecting a Sample, and shall document the details of the Athlete’s delay in reporting to the Doping Control Station.

4.8 If, while keeping the Athlete under observation, Sample Collection Personnel observe any matter with potential to compromise the test, the circumstances shall be reported to and documented by the Lead DCO/DCO. If deemed appropriate by the Lead DCO/DCO, the Lead DCO/DCO shall follow the requirements of Annex A: Investigating a possible Failure to Comply and/or consider if it is appropriate to collect an additional Sample from the Athlete.

5. Preparing for the Sample Collection Session

5.1 Objective

To prepare for the Sample Collection Session in a manner that ensures that the session can be conducted efficiently and effectively.

5.2 General

Preparing for the Sample Collection Session starts with the establishment of a system for obtaining relevant information for effective conduct of the session and ends when it is confirmed that the Sample Collection Equipment conforms


to the specified criteria. The main activities are;

a) Establishing a system for collecting details regarding the Sample Collection Session;

b) Establishing criteria for who may be present during a Sample Collection Session;

c) Ensuring that the Doping Control Station meets the minimum criteria prescribed in Procedure 5.3.2; and

d) Ensuring that Sample Collection Equipment used by BEGOC meets the minimum criteria prescribed in Procedure 5.3.5.

5.3 Requirements for preparing for the Sample Collection Session

5.3.1 BEGOC shall obtain all the information necessary to ensure that the Sample Collection Session can be conducted effectively and efficiently, including special requirements to meet the needs of Athletes with Impairments as provided in Annex B: Modifications for Athletes with Impairments as well as the needs of Athletes who are Minors as provided in Annex C: Modifications for Athletes who are Minors.

5.3.2 The VMM/Lead DCO/DCO shall use a Doping Control Station which at a minimum, ensures the Athlete’s privacy and where possible is used solely as a Doping Control Station for the duration of the Sample Collection Session. The VMM/Lead DCO shall record any significant deviations from these criteria.

5.3.3 Doping Control Stations will be located at all Competition venues and at the Athlete Villages. The VMM/Lead DCO are responsible for managing the Doping Control operations and the Doping Control workforce at a venue and in the Doping Control Station.

5.3.4 The following procedures establish the criteria for who may be present during the Sample Collection Session in addition to the Sample Collection Personnel and members of the BEGOC Medical and Anti-Doping function, including:


a) An Athlete’s entitlement to be accompanied by a representative and/or interpreter during the Sample Collection Session except when the Athlete is passing a urine Sample;

b) A Minor Athlete’s entitlement (as provided in Annex C – Modifications for Athletes who are Minors), and the witnessing DCO’s entitlement to have a representative observe the witnessing DCO when the Minor Athlete is passing a urine Sample, but without the representative directly observing the passing of the Sample unless requested to do so by the Minor Athlete;

c) An Athlete with an impairment’s entitlement to be accompanied by a representative as provided in Annex B: Modifications for Athletes with Impairments;

d) An EOC Anti-Doping Committee representative. The EOC Medical Committee representative shall not directly observe the passing of a urine Sample;

e) The relevant European Federation/International Federation representative. The European Federation/International Federation representative shall not directly observe the passing of a urine Sample; and

f) A WADA Observer where applicable under the Independent Observer Programme. The WADA Observer shall not directly observe the passing of a urine Sample.

5.3.5 The DCO shall only use Sample Collection Equipment systems that are authorised by BEGOC, which at a minimum, shall:

a) Have a unique numbering system incorporated into all bottles, containers, tubes or any other item used to seal the Sample;

b) Have a sealing system that is tamper evident;

c) Ensure the identity of the Athlete is not evident from the equipment itself; and

d) Be clean and sealed prior to use by the Athlete.


5.3.6 BEGOC will use Berlinger Sample Collection Equipment.

5.3.7 Photographs, video or tape recordings may only be taken inside the Doping Control Station with the permission of the Lead DCO and only when the Doping Control Station is not in operation. No photographs, video or tape recordings may be taken once the Doping Control Station is in operation. Mobile phones may be used as phones but not cameras. However, all mobile phones must be turned off during the processing of the Sample.

5.3.8 BEGOC shall have in place a system for recording the Chain of Custody of the Samples and Sample collection documentation which includes confirmation that both the Samples and Sample collection documentation have arrived at their intended destinations.

6. Conducting the Sample Collection Session

6.1 Objective

To conduct the Sample Collection Session in a manner that ensures the integrity, security and identity of the Sample and respects the privacy and dignity of the Athlete.

6.2 General

The Sample Collection Session starts with defining overall responsibility for the conduct of the Sample Collection Session and ends once the Sample has been collected and secured and the Sample collection documentation is complete. The main activities are:

a) Preparing for collecting the Sample;

b) Collecting and securing the Sample; and

c) Documenting the Sample collection.


6.3 Requirements prior to Sample collection

6.3.1 BEGOC and the Lead DCO shall be responsible for the overall conduct of the Sample Collection Session with specific responsibilities delegated to the DCO.

6.3.2 The DCO shall ensure that the Athlete is informed of his/her rights and responsibilities as specified in Procedure 4.1.

6.3.3 The DCO shall provide the Athlete with the opportunity to hydrate. The Athlete should avoid excessive hydration, having in mind the requirement to provide a Sample with a Suitable Specific Gravity for Analysis.

6.3.4 The Athlete shall only leave the Doping Control Station under continuous observation by the DCO or Chaperone and with the approval of the Lead DCO. The Lead DCO shall consider any reasonable request, as specified in Procedures 4.4, 4.5 and 4.6, by the Athlete to leave the Doping Control Station, until the Athlete is able to provide a Sample.

6.3.5 If the Lead DCO gives approval for the Athlete to leave the Doping Control Station, the Lead DCO shall agree with the Athlete on the following conditions of leave:

a) The purpose of the Athlete leaving the Doping Control Station;

b) The time of return (or return upon completion of an agreed activity);

c) That the Athlete must remain under continuous observation at all times;

d) That the Athlete shall not pass urine until he/she gets back to the Doping Control Station.

e) The DCO shall document the time of the Athlete’s departure and return.

6.3.6 The Lead DCO/DCO shall document this information agreed to and the actual time of the Athlete’s departure and subsequent return.


7. Requirements for Sample collection 7.1 The DCO shall collect the Sample from the Athlete according to the following procedures for the specific type of Sample collection:

a) Annex D: Collection of Urine Samples; and

b) Annex E: Collection of Blood Samples.

7.2 Any behaviour by the Athlete and/or Persons associated with the Athlete or anomalies with potential to compromise the Sample collection shall be recorded by the DCO. If appropriate, BEGOC and/or the Lead DCO/DCO shall apply Annex A: Investigating a possible Failure to Comply.

7.3 If there are doubts as to the origin or authenticity of the Sample, the Athlete shall be asked to provide an additional Sample. If the Athlete refuses to provide an additional Sample the DCO shall document in detail the circumstances around the refusal and BEGOC/EOC shall apply Annex A: Investigating a possible Failure to Comply.

7.4 The DCO shall provide the Athlete with the opportunity to document any concerns he/she may have about how the Sample Collection Session was conducted.

7.5 In conducting the Sample Collection Session the following information shall be recorded as a minimum:

a) Date, time and type of notification (no advance notice or advance notice);

b) Arrival time at Doping Control Station;

c) Date and time of completion of Sample collection process (i.e., the time when the Athlete signs the declaration at the bottom of the Doping Control form);

d) The name of the Athlete;

e) The date of birth of the Athlete;

f) The gender of the Athlete;


g) The Athlete's home address, email address and telephone number;

h) The Athlete’s sport and discipline;

i) The name of the Athlete’s coach and doctor;

j) The Sample code number;

k) The type of the Sample (urine, blood, etc);

l) The type of test (In-Competition or Out-of-Competition);

m) The name and signature of the witnessing DCO/Chaperone;

n) The name and signature of the Blood Collection Officer (where applicable);

o) Partial Sample information, as per Article F.4.4;

p) Required laboratory information on the Sample (i.e., for a urine Sample, its volume and specific gravity);

q) Medications and supplements taken within the previous seven days and (where the Sample collected is a blood Sample) blood transfusions within the previous three months, as declared by the Athlete;

r) Any irregularities in procedures;

s) Athlete comments or concerns regarding the conduct of the Sample Collection Session, as declared by the Athlete;

t) Athlete consent for the processing of Sample collection data;

u) Athlete consent or otherwise for the use of the Sample(s) for research purposes;

v) The name and signature of the Athlete’s representative (if applicable), as per Procedure 7.4;

w) The name and signature of the Athlete;


x) The name and signature of the DCO;

y) The name of the Testing Authority;

z) The name of the Sample Collection Authority; and

aa) The name of the Results Management Authority.

7.4 At the conclusion of the Sample Collection Session the Athlete and DCO shall sign appropriate documentation to indicate their satisfaction that the documentation accurately reflects the details of the Athlete’s Sample Collection Session, including any concerns recorded by the Athlete. The Athlete’s representative (if any) and the Athlete shall both sign the documentation if the Athlete is a Minor. Other Persons present who had a formal role during the Athlete’s Sample Collection Session may sign the documentation as a witness of the proceedings.

7.5 The DCO shall provide the Athlete with a copy of the records of the Sample Collection Session that have been signed by the Athlete.

8. Security/post-test administration

8.1 Objective

To ensure that all Samples collected at the Doping Control Station and Sample collection documentation are securely stored prior to their departure from the Doping Control Station.

8.2 General

Post-test administration begins when the Athlete leaves the Doping Control Station after providing a Sample(s), and ends with preparation of all of the collected Samples and Sample collection documentation for transport.

8.3 Requirements for security/post-test administration

8.3.1 BEGOC has established criteria to ensure that any Sample will be stored in a manner that protects its integrity, identity and security prior to transport


from the Doping Control Station. The VMM/Lead DCO shall ensure that any Sample is stored in accordance with these criteria.

8.3.2 Without exception, all Samples collected shall be sent for analysis to a WADA-accredited laboratory or as otherwise approved by WADA.

8.3.3 The Lead DCO shall ensure that the documentation for each Sample is completed and securely handled.

8.3.4 BEGOC shall ensure that, where required, instructions for the type of analysis to be conducted are provided to the WADA-accredited laboratory. In addition, the EOC/BEGOC shall provide the laboratory with information as required under Procedure 7.5 c), f), h), j), k), l), o), p), q), y), z) and aa) for result reporting and statistical purposes.

9. Transport of Samples and documentation

9.1 Objective

a) To ensure that Samples and related documentation arrive at the WADA-accredited laboratory in proper condition to do the necessary analysis; and

b) To ensure the Sample Collection Session documentation is sent by the VMM/Lead DCO/DCO to the EOC in a secure and timely manner.

9.2 General

9.2.1 Transport starts when the Samples and related documentation leave the Doping Control Station and ends with the confirmed receipt of the Samples and Sample Collection Session documentation at their intended destinations.

9.2.2 The main activities are arranging for the secure transport of Samples and related documentation to the WADA-accredited laboratory, and arranging for the secure transport of Sample Collection Session documentation to the EOC.


10. Requirements for transport and storage of Samples and documentation 10.1 BEGOC has authorised a transport system that ensures Samples and documentation will be transported in a manner that protects their integrity, identity and security.

10.2 Samples shall always be transported to the WADA-accredited laboratory using a BEGOC authorised transport method as soon as practicable after the completion of the Sample Collection Session. Samples shall be transported in a manner which minimises the potential for Sample degradation due to factors such as time delays and extreme temperature variations.

10.3 Documentation identifying the Athlete shall not be included with the Samples or documentation sent to the WADA-accredited laboratory or as otherwise approved by WADA.

10.4 BEGOC shall send all relevant Sample Collection Session documentation to the EOC using a BEGOC authorised transport method as soon as practicable after the completion of the Sample Collection Session. When required, the VMM/Lead DCO shall complete all necessary documentation for customs purposes.

10.5 Chain of Custody shall be checked by BEGOC if receipt of either the Samples with accompanying documentation or Sample collection documentation is not confirmed at their intended destination or a Sample’s integrity or identity may have been compromised during transport. In this instance, BEGOC shall inform the EOC and the EOC shall consider whether the Sample should be voided. The opening of the transport bag by customs, border authorities or BEGOC security staff will not, in itself, invalidate laboratory results.

10.6 Documentation related to a Sample Collection Session and/or an anti-doping rule violation shall be stored by the EOC for the periods specified in Annex A to the International Standard on Protection of Privacy and Personal Information.


11. Ownership of Samples The EOC owns the Samples collected from the Athlete. The EOC may transfer ownership of the Samples to an Anti-Doping Organization with Results Management or to another Anti-Doping Organization upon request.


Annex A - Investigating a Possible Failure to Comply

A.1 Objective

To ensure that any matters occurring before, during or after a Sample Collection Session that may lead to a determination of a Failure to Comply are properly assessed, documented and acted upon.

A.2 Scope

Investigating a possible Failure to Comply begins when the EOC, BEGOC or a DCO becomes aware of a possible Failure to Comply and ends when the EOC takes appropriate follow-up action based on the outcome of its investigation.

A.3 Responsibility

A.3.1 The EOC is responsible for ensuring that:

a) when the possible Failure to Comply comes to its attention, it notifies WADA, and instigates an investigation of the possible Failure to Comply based on all relevant information and documentation;

b) the Athlete or other party is informed of the possible Failure to Comply in writing and has the opportunity to respond;

c) the investigation is conducted without unnecessary delay and the evaluation process is documented; and

d) the final determination (i.e., whether or not to assert the commission of an anti-doping rule violation), with reasons, is made available without delay to WADA and other Anti-Doping Organizations in accordance with Code Articles 7.10 and 14.1.4.

A.3.2 The DCO is responsible for:

a) informing the Athlete or other party of the Consequences of a possible Failure to Comply;


b) completing the Athlete’s Sample Collection Session where possible; and

c) providing a detailed written report of any possible Failure to Comply.

A.3.3 Sample Collection Personnel are responsible for:

a) informing the Athlete or other party of the Consequences of a possible Failure to Comply; and

b) reporting to the DCO any possible Failure to Comply.

A.4 Requirements

A.4.1 Any potential Failure to Comply shall be reported by the DCO and/or followed up by the EOC as soon as practicable.

A.4.2 If the EOC determines that there has been a potential Failure to Comply, the Athlete or other party shall be promptly notified in writing:

a) of the possible Consequences; and

b) that the potential Failure to Comply will be investigated by the EOC and appropriate follow-up action will be taken.

A.4.3 Any additional necessary information about the potential Failure to Comply shall be obtained from all relevant sources (including the Athlete or other party) as soon as possible and recorded.

A.4.4 The EOC shall establish a system for ensuring that the outcomes of its investigation into the potential Failure to Comply are considered for results management action and, if applicable, for further planning and Target Testing.


Annex B - Modifications for Athletes with Impairments

B.1 Objective

To ensure that the particular needs of Athletes with Impairments are considered in relation to the provision of a Sample, where possible, without compromising the integrity of the Sample Collection Session.

B.2 Scope

Determining whether modifications are necessary starts with identification of situations where Sample collection involves Athletes with Impairments and ends with modifications to Sample collection procedures and equipment where necessary and where possible.

B.3 Responsibility

B.3.1 BEGOC has responsibility for ensuring, when possible, that the DCO has any information and Sample Collection Equipment necessary to conduct a Sample Collection Session with an Athlete with an impairment.

B.3.2 The DCO has responsibility for Sample collection.

B.4 Requirements

B.4.1 All aspects of notification and Sample collection for Athletes with Impairments shall be carried out in accordance with the standard notification and Sample collection procedures unless modifications are necessary due to the Athlete’s impairment. [Comment to B.4.1: For example, it may be appropriate, in the case of an Athlete with an intellectual impairment, to obtain consent to Testing from his/her representative.]

B.4.2 In planning or arranging Sample collection, BEGOC and DCO shall consider whether there will be any Sample collection for Athletes with Impairments that may require modifications to the standard procedures for notification or Sample collection, including Sample Collection Equipment and facilities.


B.4.3 The Sample Collection Authority and DCO shall have the authority to make modifications as the situation requires when possible and as long as such modifications will not compromise the identity, security or integrity of the Sample. All such modifications must be documented.

B.4.4 An Athlete with an intellectual, physical or sensorial impairment may be assisted by the Athlete’s representative or Sample Collection Personnel during the Sample Collection Session where authorized by the Athlete and agreed to by the DCO.

B.4.5 The DCO may decide that alternative Sample Collection Equipment or facilities will be used when required to enable the Athlete to provide the Sample, as long as the Sample’s identity, security and integrity will not be affected.

B.4.6 Athletes who are using urine collection or drainage systems are required to eliminate existing urine from such systems before providing a urine Sample for analysis. Where possible, the existing urine collection or drainage system should be replaced with a new, unused catheter or drainage system prior to collection of the Sample. The catheter or drainage system is not a required part of Sample Collection Equipment to be provided by the Sample Collection Authority; instead it is the responsibility of the Athlete to have the necessary equipment available for this purpose.

B.4.7 The DCO will record modifications made to the standard Sample collection procedures for Athletes with Impairments, including any applicable modifications specified in the above actions.


Annex C - Modifications for Athletes who are Minors

C.1 Objective

To ensure that the particular needs of Athletes who are Minors are met in relation to the provision of a Sample, where possible, without compromising the integrity of the Sample Collection Session.

C.2 Scope

Determining whether modifications are necessary starts with identification of situations where Sample collection involves Athletes who are Minors and ends with modifications to Sample collection procedures where necessary and where possible.

C.3 Responsibility

The EOC has responsibility for ensuring, when possible, that the DCO has any information necessary to conduct a Sample Collection Session with an Athlete who is a Minor. This includes confirming wherever necessary that the organiser of the Event obtains the necessary parental consent for Testing any participating Athlete who is a Minor.

C.4 Requirements

C.4.1 All aspects of notification and Sample collection for Athletes who are Minors shall be carried out in accordance with the standard notification and Sample collection procedures unless modifications are necessary due to the Athlete being a Minor.

C.4.2 In planning or arranging Sample collection, BEGOC and the DCO shall consider whether there will be any Sample collection for Athletes who are Minors that may require modifications to the standard procedures for notification or Sample collection.

C.4.3 The DCO and BEGOC shall have the authority to make modifications as the situation requires when possible and as long as such modifications will not


compromise the identity, security or integrity of the Sample.

C.4.4 Athletes who are Minors should be notified in the presence of an adult, and may choose to be accompanied by a representative throughout the entire Sample Collection Session. The representative shall not witness the passing of a urine Sample unless requested to do so by the Minor. The objective is to ensure that the DCO is observing the Sample provision correctly. Even if the Minor declines a representative, BEGOC, the DCO or Chaperone, as applicable, shall consider whether another third party ought to be present during notification of and/or collection of the Sample from the Athlete.

C.4.5 The DCO shall determine who (in addition to the Sample Collection Personnel) may be present during the collection of a Sample from an Athlete who is a Minor, namely a representative of the Minor to observe the Sample Collection Session (including observing the DCO when the Minor is passing the urine Sample, but not directly observing the passing of the urine Sample unless requested to do so by the Minor) and the DCO’s/Chaperone’s representative, to observe the DCO/Chaperone when a Minor is passing a urine Sample, but without the representative directly observing the passing of the Sample unless requested by the Minor to do so.

C.4.6 Should an Athlete who is a Minor decline to have a representative present during the Sample Collection Session, this should be clearly documented by the DCO. This does not invalidate the test, but must be recorded. If a Minor declines the presence of a representative, the representative of the DCO/Chaperone must be present.

C.4.7 The preferred venue for all Out-of-Competition Testing of a Minor is a location where the presence of an adult is most likely, e.g., a training venue.

C.4.8 BEGOC shall consider the appropriate course of action when no adult is present at the Testing of an Athlete who is a Minor and shall accommodate the Athlete in locating a representative in order to proceed with Testing.


Annex D - Collection of Urine Samples D.1 Objective

To collect an Athlete’s urine Sample in a manner that ensures:

a) consistency with relevant principles of internationally recognised standard precautions in healthcare settings so that the health and safety of the Athlete and Sample Collection Personnel are not compromised;

b) the Sample meets the Suitable Specific Gravity for Analysis and the Suitable Volume of Urine for Analysis. Failure of a Sample to meet these requirements in no way invalidates the suitability of the Sample for analysis. The determination of a Sample’s suitability for analysis is the decision of the relevant laboratory, in consultation with the EOC for the Sample Collection Session in question;

c) the Sample has not been manipulated, substituted, contaminated or otherwise tampered with in any way;

d) the Sample is clearly and accurately identified; and

e) the Sample is securely sealed in a tamper-evident kit.

D.2 Scope

The collection of a urine Sample begins with ensuring the Athlete is informed of the Sample collection requirements and ends with discarding any residual urine remaining at the end of the Athlete’s Sample Collection Session.

D.3 Responsibility

D.3.1 The DCO has the responsibility for ensuring that each Sample is properly collected, identified and sealed.

D.3.2 The DCO/Chaperone has the responsibility for directly witnessing the passing of the urine Sample.


D.4 Requirements

D.4.1 The DCO shall ensure that the Athlete is informed of the requirements of the Sample Collection Session, including any modifications as provided for in Annex B – Modifications for Athletes with Impairments.

D.4.2 The DCO shall ensure that the Athlete is offered a choice of appropriate equipment for collecting the Sample. If the nature of an Athlete’s impairment requires that he/she must use additional or other equipment as provided for in Annex B – Modifications for Athletes with Impairments, the DCO shall inspect that equipment to ensure that it will not affect the identity or integrity of the Sample.

D.4.3 The DCO shall instruct the Athlete to select a collection vessel.

D.4.4 When the Athlete selects a collection vessel, and for selection of all other Sample Collection Equipment that directly holds the urine Sample, the DCO will instruct the Athlete to check that all seals on the selected equipment are intact and the equipment has not been tampered with. If the Athlete is not satisfied with the selected equipment, he/she may select another. If the Athlete is not satisfied with any of the equipment available for selection, this shall be recorded by the DCO. If the DCO does not agree with the Athlete that all of the equipment available for the selection is unsatisfactory, the DCO shall instruct the Athlete to proceed with the Sample Collection Session. If the DCO agrees with the Athlete that all of the equipment available for the selection is unsatisfactory, the DCO shall terminate the Sample Collection Session and this shall be recorded by the DCO.

D.4.5 The Athlete shall retain control of the collection vessel and any Sample provided until the Sample (or partial Sample) is sealed, unless assistance is required by reason of an Athlete’s impairment as provided for in Annex B – Modifications for Athletes with Impairments. Additional assistance may be provided in exceptional circumstances to any Athlete by the Athlete’s representative or Sample Collection Personnel during the Sample Collection Session where authorised by the Athlete and agreed to by the DCO.

D.4.6 The DCO/Chaperone who witnesses the passing of the Sample shall be of the same gender as the Athlete providing the Sample.


D.4.7 The DCO/Chaperone should, where practicable, ensure the Athlete thoroughly washes his/her hands prior to the provision of the Sample or wears suitable (e.g., latex) gloves during provision of the Sample.

D.4.8 The DCO/Chaperone and Athlete shall proceed to an area of privacy to collect a Sample.

D.4.9 The DCO/Chaperone shall ensure an unobstructed view of the Sample leaving the Athlete’s body and must continue to observe the Sample after provision until the Sample is securely sealed. In order to ensure a clear and unobstructed view of the passing of the Sample, the DCO/Chaperone shall instruct the Athlete to remove or adjust any clothing which restricts the DCO’s/Chaperone’s clear view of Sample provision. The DCO/Chaperone shall ensure that all urine passed by the Athlete at the time of provision of the Sample is collected in the collection vessel.

D.4.10 The DCO shall verify, in full view of the Athlete, that the Suitable Volume of Urine for Analysis has been provided.

D.4.11 Where the volume of urine provided by the Athlete is insufficient, the DCO shall follow the partial Sample collection procedure set out in Annex F – Urine Samples – Insufficient Volume.

D.4.12 Once the volume of urine provided by the Athlete is sufficient, the DCO shall instruct the Athlete to select a Sample collection kit containing A and B bottles in accordance with Article D.4.4.

D.4.13 Once a Sample collection kit has been selected, the DCO and the Athlete shall check that all code numbers match and that this code number is recorded accurately by the DCO on the Doping Control form. If the Athlete or DCO finds that the numbers are not the same, the DCO shall instruct the Athlete to choose another kit in accordance with Article D.4.4. The DCO shall record the matter.

D.4.14 The Athlete shall pour the minimum Suitable Volume of Urine for Analysis into the B bottle (to a minimum of 30 mL), and then pour the remainder of the urine into the A bottle (to a minimum of 60 mL). The Suitable Volume of Urine for Analysis shall be viewed as an absolute minimum. If more than the minimum Suitable Volume of Urine for Analysis has been provided,


the DCO shall ensure that the Athlete fills the A bottle to capacity as per the recommendation of the equipment manufacturer. Should there still be urine remaining, the DCO shall ensure that the Athlete fills the B bottle to capacity as per the recommendation of the equipment manufacturer. The DCO shall instruct the Athlete to ensure that a small amount of urine is left in the collection vessel, explaining that this is to enable the DCO to test that residual urine in accordance with Article D.4.16.

D.4.15 The Athlete shall then seal the A and B bottles as directed by the DCO. The DCO shall check, in full view of the Athlete, that the bottles have been properly sealed.

D.4.16 The DCO shall test the residual urine in the collection vessel to determine if the Sample has a Suitable Specific Gravity for Analysis. If the DCO’s field reading indicates that the Sample does not have a Suitable Specific Gravity for Analysis, then the DCO shall follow Annex G (Urine Samples that do not meet the requirement for Suitable Specific Gravity for Analysis).

D.4.17 Urine should only be discarded when both the A and B bottles have been filled to capacity in accordance with Article D.4.14 and the residual urine has been tested in accordance with Article D.4.16.

D.4.18 The Athlete shall be given the option of witnessing the discarding of any residual urine that will not be sent for analysis.


Annex E - Collection of Blood Samples E.1 Objective

To collect an Athlete’s blood Sample in a manner that ensures:

a) consistency with relevant principles of internationally recognised standard precautions in healthcare settings, and is collected by a suitably qualified person, so that the health and safety of the Athlete and Sample Collection Personnel are not compromised;

b) the Sample is of a quality and quantity that meets the relevant analytical guidelines;

c) that Samples intended for use in connection with the measurement of individual Athlete blood variables within the framework of the Athlete Biological Passport programme are collected in a manner appropriate for such use.

d) the Sample has not been manipulated, substituted, contaminated or otherwise tampered with in any way;

e) the Sample is clearly and accurately identified; and

f) the Sample is securely sealed.

E.2 Scope

The collection of a blood Sample begins with ensuring the Athlete is informed of the Sample collection requirements and ends with properly storing the Sample prior to transport to the laboratory that will be analysing the Sample.

E.3 Responsibility

E.3.1 The DCO has the responsibility for ensuring that:

a) Each Sample is properly collected, identified and sealed; and


b) All Samples have been properly stored and dispatched in accordance with the relevant analytical guidelines.

E.3.2 The Blood Collection Officer (BCO) has the responsibility for collecting the blood Sample, answering related questions during the provision of the Sample, and proper disposal of used blood sampling equipment not required to complete the Sample Collection Session.

E.4 Requirements

E.4.1 Procedures involving blood shall be consistent with the local standards and regulatory requirements regarding precautions in healthcare settings where those standards and requirements exceed the requirements set out below.

E.4.2 Blood Sample Collection Equipment shall consist of (a) a single Sample tube for Samples to be used in connection with an Athlete Biological Passport programme; or (b) both an A and B sample tube for Samples not to be used in connection with an Athlete Biological Passport programme; or (c) other equipment as otherwise specified by the relevant laboratory. Collection tubes shall be labelled with a unique Sample code number by the DCO/BCO if they are not pre-labelled. The types of equipment to be used and the volume of blood to be collected for particular analyses shall be as set out in WADA's Blood Collection Guidelines.

E.4.3 The DCO shall ensure that the Athlete is properly notified of the requirements of the Sample collection, including any modifications as provided for in Annex B – Modifications for Athletes with Impairments. If the Sample is to be used in connection with the Athlete Biological Passport programme, the DCO/BCO shall use the Doping Control form that is specific to the Athlete Biological Passport programme. If such form is not available, the DCO/BCO shall use a regular Doping Control form, but he/she shall collect and record the following additional information on a supplementary report form that shall be signed by the Athlete and the DCO/BCO:

a) confirmation that the Athlete did not participate in training or Competition in the last two hours before the Sample was collected (see Article E.4.5);

b) whether the Athlete trained, competed or resided at an altitude greater


than 1000 meters in the previous two weeks. If so, or if in doubt, the name and location of the place(s) where the Athlete has been, as well as the duration of his/her stay there, shall be recorded, along with the estimated altitude there (if known).

c) whether the Athlete used any form of altitude simulation (such as a hypoxy tent, mask, etc.) in the previous two weeks. If so, as much information as possible on the type of device and the manner in which it was used (frequency, duration, intensity, etc.) should be recorded; and

d) whether the Athlete received any blood transfusion(s) during the previous three months. Whether there was any blood loss due to accident, pathology or donation in the previous three months. In either case, if so, the estimated volume.

E.4.4 The DCO/Chaperone and Athlete shall proceed to the area where the Sample will be provided.

E.4.5 The DCO/BCO shall ensure the Athlete is offered comfortable conditions and shall instruct the Athlete to remain in a normal seated position with feet on the floor for at least 10 minutes prior to providing a Sample. If the Sample is to be used in connection with the Athlete Biological Passport programme, it shall not be collected within two hours of the Athlete training or competing. If the Athlete has trained or competed within two hours of the time that the Athlete is notified of his/her selection for Sample collection, the DCO/BCO/Chaperone shall monitor the Athlete continuously until the two hour period has elapsed, after which the Sample shall be collected. The nature of the exertion (Competition, training, etc.), as well as its duration and general intensity, shall be recorded by the DCO/BCO in the mission documentation.

E.4.6 The DCO shall instruct the Athlete to select the Sample collection kit(s) required for collecting the Sample and to check that the selected equipment has not been tampered with and the seals are intact. If the Athlete is not satisfied with a selected kit, he/she may select another. If the Athlete is not satisfied with any kits and no others are available, this shall be recorded by the DCO. If the DCO does not agree with the Athlete that all of the available kits are unsatisfactory, the DCO shall instruct the Athlete to proceed with the Sample Collection Session. If the DCO agrees with the Athlete that all available kits are unsatisfactory, the DCO shall terminate the Sample Collection Session


and this shall be recorded by the DCO.

E.4.7 When a Sample collection kit has been selected, the DCO and the Athlete shall check that all code numbers match and that this code number is recorded accurately by the DCO on the Doping Control form. If the Athlete or DCO finds that the numbers are not the same, the DCO shall instruct the Athlete to choose another kit. The DCO shall record the matter.

E.4.8 The BCO shall clean the skin with a sterile disinfectant wipe or swab in a location unlikely to adversely affect the Athlete or his/her performance and, if required, apply a tourniquet. The BCO shall take the blood Sample from a superficial vein into the tube. The tourniquet, if applied, shall be immediately removed after the venipuncture has been made.

E.4.9 The amount of blood removed shall be adequate to satisfy the relevant analytical requirements for the Sample analysis to be performed, as set out in WADA’s Blood Collection Guidelines.

E.4.10 If the amount of blood that can be removed from the Athlete at the first attempt is insufficient, the BCO shall repeat the procedure up to a maximum of three attempts in total. Should all three attempts fail to produce a sufficient amount of blood, then the BCO shall inform the DCO. The DCO shall terminate the Sample Collection Session and record this and the reasons for terminating the collection.

E.4.11 The BCO shall apply a dressing to the puncture site(s).

E.4.12 The BCO shall dispose of used blood sampling equipment not required to complete the Sample Collection Session in accordance with the required local standards for handling blood.

E.4.13 If the Sample requires further on-site processing, such as centrifugation or separation of serum (for example, in the case of a Sample intended for use in connection with the Athlete Biological Passport programme, after the blood flow into the tube ceases, the BCO shall remove the tube from the holder and homogenize the blood in the tube manually by inverting the tube gently at least three times), the Athlete shall remain to observe the Sample until final sealing in secure, tamper-evident kit.


E.4.14 The Athlete shall seal his/her Sample into the Sample collection kit as directed by the DCO. In full view of the Athlete, the DCO shall check that the sealing is satisfactory. The Athlete and the BCO/DCO shall sign the Doping Control form.

E.4.15 If the Sample is intended for use in connection with an Athlete Biological Passport programme, the DCO/BCO shall place it in a storage device that is capable of maintaining blood Samples at a cool temperature for the duration of the period of storage and transport but without allowing whole blood Samples to freeze (such as a refrigerator, an insulated cool box, an isotherm bag, or any other device with such capability). A temperature data logger shall be used to record the temperature of the Sample during storage and transport. In choosing the storage device, the Sample Collection Authority shall take into account the duration of the period of storage and transport, the number of Samples to be stored together, and the prevailing environmental conditions (hot or cold temperatures).

E4.16 The sealed Sample shall be stored in a manner that protects its integrity, identity and security prior to transport from the Doping Control Station to the laboratory that will be analysing the Sample.

E.4.17 Blood Samples shall be transported in accordance with Procedure 9.0. The transport procedure is the responsibility of the VMM/Lead DCO/DCO as applicable. Blood Samples shall be transported in a device that maintains the integrity of Samples over time notwithstanding changes in external temperature. The transport device shall be transported by secure means using a method authorized by the EOC. If the Sample is intended for use in connection with an Athlete Biological Passport programme, it shall be transported rapidly to the laboratory so that analysis can be performed ideally within 36 hours of Sample collection.


Annex F - Urine Samples - Insufficient Volume

F.1 Objective

To ensure that where a Suitable Volume of Urine for Analysis is not provided, appropriate procedures are followed.

F.2 Scope

The procedure begins with informing the Athlete that the Sample that he/she has provided is not of Suitable Volume of Urine for Analysis and ends with the Athlete’s provision of a Sample of sufficient volume.

F.3 Responsibility

The DCO has the responsibility for declaring the Sample volume insufficient and for collecting the additional Sample(s) to obtain a combined Sample of sufficient volume.

F.4 Requirements

F.4.1 If the Sample collected is of insufficient volume, the DCO shall inform the Athlete that a further Sample shall be collected to meet the Suitable Volume of Urine for Analysis requirements.

F.4.2 The DCO shall instruct the Athlete to select partial Sample Collection Equipment in accordance with Article D.4.4.

F.4.3 The DCO shall then instruct the Athlete to open the relevant equipment, pour the insufficient Sample into the new container and seal it as directed by the DCO. The DCO shall check, in full view of the Athlete, that the container (or original collection vessel, if applicable) has been properly sealed.

F.4.4 The DCO and the Athlete shall check that the equipment code number and the volume and identity of the insufficient Sample are recorded accurately by the DCO on the Doping Control form. Either the Athlete or the DCO shall retain control of the sealed partial Sample.


F.4.5 While waiting to provide an additional Sample, the Athlete shall remain under continuous observation and be given the opportunity to hydrate.

F.4.6 When the Athlete is able to provide an additional Sample, the procedures for collection of the Sample shall be repeated as prescribed in Annex D – Collection of Urine Samples until a sufficient volume of urine will be provided by combining the initial and additional Sample(s).

F.4.7 When the DCO is satisfied that the requirements for Suitable Volume of Urine for Analysis have been met, the DCO and Athlete shall check the integrity of the seal(s) on the container(s) containing the previously provided partial Sample(s). Any irregularity with the integrity of the seal(s) will be recorded by the DCO and investigated according to Annex A – Investigating a Possible Failure to Comply.

F.4.8 The DCO shall then direct the Athlete to break the seal(s) and combine the Samples, ensuring that additional Samples are added in the order they were collected to the original partial Sample until, as a minimum, the requirement for Suitable Volume of Urine for Analysis is met.

F.4.9 The DCO and the Athlete shall then continue with Article D.4.12 or Article D.4.14 as appropriate.

F.4.10 The DCO shall check the residual urine in accordance with Article D.4.16 to ensure that it meets the requirement for Suitable Specific Gravity for Analysis.

F.4.11 Urine should only be discarded when both the A and B bottles have been filled to capacity in accordance with Article D.4.14 and the residual urine has been checked in accordance with Article F.4.10. The Suitable Volume of Urine for Analysis shall be viewed as an absolute minimum.


Annex G - Urine Samples that do not meet the requirement for Suitable Specific Gravity for Analysis

G.1 Objective

To ensure that when the urine Sample does not meet the requirement for Suitable Specific Gravity for Analysis, appropriate procedures are followed.

G.2 Scope

The procedure begins with the DCO informing the Athlete that a further Sample is required and ends with the collection of a Sample that meets the requirements for Suitable Specific Gravity for Analysis, or appropriate follow-up action by the EOC if required.

G.3 Responsibility

BEGOC is responsible for establishing procedures to ensure that a suitable Sample is collected. If the original Sample collected does not meet the requirement for Suitable Specific Gravity for Analysis, the DCO is responsible for collecting additional Samples until a suitable Sample is obtained.

G.4 Requirements

G.4.1 The DCO shall determine that the requirements for Suitable Specific Gravity for Analysis have not been met.

G.4.2 The DCO shall inform the Athlete that he/she is required to provide a further Sample.

G.4.3 While waiting to provide a further Sample, the Athlete shall remain under continuous observation.

G.4.4 The Athlete shall be advised not to hydrate excessively, since this may delay the production of a suitable Sample. In appropriate circumstances, excessive hydration may be pursued as a violation of Code Article 2.5


(Tampering or Attempted Tampering with any part of Doping Control).

G.4.5 When the Athlete is able to provide an additional Sample, the DCO shall repeat the procedures for Sample collection set out in Annex D – Collection of Urine Samples.

G.4.6 The DCO should continue to collect additional Samples until the requirement for Suitable Specific Gravity for Analysis is met, or until the DCO determines that there are exceptional circumstances which mean that for logistical reasons it is impossible to continue with the Sample Collection Session. Such exceptional circumstances shall be documented accordingly by the DCO.

G.4.7 In accordance with Article G.4.6, given the logistical nature of the Games, it would typically be impossible to collect more than two (2) Samples from the Athletes during one Doping Control session. As such, the EOC will typically require Athletes to provide one (1) additional Sample in the event the Athlete’s Sample does not meet the requirements for Suitable Specific gravity for Analysis.

G.4.8 The DCO shall record that the Samples collected belong to a single Athlete and the order in which the Samples were provided.

G.4.9 The DCO shall then continue with the Sample Collection Session in accordance with Article D.4.17.

G.4.10 If it is determined that none of the Samples collected from the Athlete meets the requirement for Suitable Specific Gravity for Analysis and the DCO determines that for logistical reasons it is impossible to continue with the Sample Collection Session, the DCO may end the Sample Collection Session.

G.4.11 The DCO shall send to the laboratory for analysis all Samples which were collected, irrespective of whether or not they meet the requirement for Suitable Specific Gravity for Analysis.

G.4.12 The laboratory shall determine, in conjunction with the EOC, which Samples shall be analysed.


Annex H - Sample Collection Personnel Requirements

H.1 Objective

To ensure that Sample Collection Personnel have no conflict of interest and have adequate qualifications and experience to conduct Sample Collection Sessions.

H.2 Scope

Sample Collection Personnel requirements start with the development of the necessary competencies for Sample Collection Personnel and end with the provision of identifiable accreditation.

H.3 Responsibility

BEGOC has the ultimate responsibility for all activities defined in this Annex H. However, certain activities have been delegated to the Doping Control Supplier (PWC Global Service GmbH & Co. KG).

H.4 Requirements – Qualifications and Training

H.4.1 BEGOC shall ensure that the Doping Control Supplier will:

a) determine the necessary competence and qualification requirements for the positions of DCO, Chaperone and BCO; and

b) develop duty statements for all Sample Collection Personnel that outline their respective responsibilities. As a minimum:

i) Sample Collection Personnel shall not be Minors; and

ii) BCOs shall have adequate qualifications and practical skills required to perform blood collection from a vein.


H.4.2 BEGOC shall ensure that Sample Collection Personnel that have an interest in the outcome of a Sample Collection Session are not appointed to that Sample Collection Session. Sample Collection Personnel are deemed to have such an interest if they are:

a) Involved in the administration of the sport for which Testing is being conducted; or

b) Related to, or involved in the personal affairs of, any Athlete who might provide a Sample at that session.

H.4.3 BEGOC shall ensure that the Doping Control Supplier establishes a system that ensures that Sample Collection Personnel are adequately trained to carry out their duties.

H.4.3.1 The training programme for BCOs shall include, as a minimum, studies of all relevant requirements of the Testing process and familiarization with relevant standard precautions in healthcare settings.

H.4.3.2 The training programme for DCOs shall include, as a minimum:

a) Comprehensive theoretical training in different types of Testing activities relevant to the DCO position;

b) Observation of all Doping Control activities that are the responsibility of the DCO as set out in this International Standard for Testing and Investigations, preferably on-site; and

c) The satisfactory performance of one complete Sample Collection Session on site under observation by a qualified DCO or similar. The requirement related to the actual passing of a urine Sample shall not be included in the on-site observations.

H.4.3.3 The training programme for Chaperones shall include studies of all relevant requirements of the Sample collection process.

H.4.3.4 BEGOC shall ensure that the Doping Control Supplier establish additional systems to ensure that Sample Collection Personnel are adequately


trained to carry out their duties in respect of Athletes who are of a different nationality to its Sample Collection Personnel.

H 4.4 BEGOC shall ensure that the Doping Control Supplier maintains records of education, training, skills and experience of all Sample Collection Personnel.

H.5 Requirements - Accreditation, re-accreditation and delegation

H.5.1 BEGOC shall ensure that the Doping Control Supplier establishes a system for accrediting and re-accrediting Sample Collection Personnel.

H.5.2 BEGOC shall ensure that Sample Collection Personnel have completed the training programme and are familiar with the requirements of this International Standard for Testing and Investigations (including, where Article H.4.3.4 applies, in relation to the collection of Samples from Athletes who are of a different nationality to the Sample Collection Personnel) before granting accreditation.

H.5.3 Accreditation shall only be valid for a maximum of two years. Sample Collection Personnel shall be required to repeat a full training programme if they have not participated in Sample collection activities within the year prior to re-accreditation.

H.5.4 Only Sample Collection Personnel who have an accreditation recognised by BEGOC shall be authorised to conduct Sample collection activities on behalf of BEGOC.

H.5.5 DCOs may personally perform any activities involved in the Sample Collection Session, with the exception of blood collection unless particularly qualified, or they may direct a Chaperone to perform specified activities that fall within the scope of the Chaperone’s authorised duties.

Pharmacy Guide


1. Pharmacy organisationThe BEGOC Pharmacy Service will provide medicines for immediate and necessary treatment for athletes and members of the European Games Family during the Games from the Athlete Village Polyclinic and from competition venues. A medicines information service will also be provided.

1.1 Location

The Baku 2015 Pharmacy will be located within the Athlete Village Polyclinic. All individuals accredited for the Residential Zone of the Athlete Village will have access to the pharmacy.

1.2 Hours of operation

The pharmacy will be open from 07:00 to 23:00 between 8 June and 1 July 2015.

There will be access to emergency medicines only overnight via the Duty Polyclinic Manager. There will be a limited amount of medicines available in the Canoe Sprint Village medical clinic. These will be dispensed from the medical clinic. Medicines not stocked in the medical clinic will be provided within a minimum of two hours. The Baku 2015 prescriptions will be acceptable only.

1.3 Medicines Information Service

A Medicines Information Service will be provided by pharmacists from the Polyclinic Pharmacy and will offer information on:

• Clinical drug information

• International medicines

• Prohibited status of drugs in sport

• Prescribing procedures


2. Prescription overview The pharmacy will only provide the medicines listed in this Pharmacy Guide. They will be provided free of charge from the Polyclinic Pharmacy to individuals as part of their medical treatment on an immediate and necessary basis.

Medicines will only be dispensed against an official Baku 2015 prescription form, written either by accredited Baku 2015 doctors or by accredited NOC doctors registered to prescribe in Azerbaijan. All prescriptions must be written in English. Prescriptions written by doctors for self-use will not be accepted - another doctor must be consulted.

Any individual with an existing medical condition should bring enough medicine with them to cover the duration of their visit to Azerbaijan and their travel home.

Only those NOC team doctors who have applied for temporary registration with the Ministry of Health will be supplied with Baku 2015 prescription forms. NOC team doctors are only allowed to prescribe for members of their own team.

2.1 Prescriptions

Up to seven days’ supply, or a small complete pack of medicine will be dispensed with a single prescription. Further supplies will require a subsequent prescription. Antibiotics may be prescribed in sufficient quantities to treat the medical condition.

3. Medicines available at venuesA limited quantity of essential medicines will be available for immediate and emergency care from the medical rooms at competition venues. Medicines will usually be issued only as a single dose for immediate treatment. The doctor can write a prescription for subsequent doses, which will be dispensed in full by the Polyclinic Pharmacy in the Athletes Village.


4. Prescribing and administering prohibited substances Prohibited substances are drugs that, according to the World Anti-Doping Code or each International Federation’s (IF) rules for a particular sport, may not be used by athletes who will be competing unless a Therapeutic Use Exemption (TUE) has been obtained in advance.

If an NOC team doctor administers or prescribes a prohibited medicine, they will be responsible for notifying the EOC Medical and Anti-doping Commission and applying for a TUE if one has not already been obtained.

Application for a new TUE should normally be submitted in writing to the EOC Medical and Anti-doping Commission before treatment, but this may be expedited by directly contacting the Chair of the EOC Medical and Anti-doping Commission at the AVL Polyclinic to obtain a verbal notification and a TUE. A written TUE will subsequently need to be submitted.

In an emergency, a doctor must treat an athlete, including using prohibited substances and methods if clinically necessary, and must apply for a retrospective TUE immediately afterwards.

If a prohibited medicine is to be administered by Baku 2015 Medical Services staff at a competition venue, training venue or Polyclinic, the Venue Medical and Anti-doping Manager or Pharmacy Services Manager must ensure that the EOC Medical and Anti-doping Commission is notified and a retrospective TUE is applied for by the treating physician.

4.1 Dispensing prohibited medicines from pharmacy

If a prescription for a prohibited medicine is required for an athlete, a copy of the TUE documentation should be presented to the dispensing pharmacist, who will then dispense the medicine for the athlete.

If a copy of the TUE cannot be presented, the athlete must sign the prescription form to confirm that a valid TUE has been obtained and that the athlete takes personal responsibility for the use of the prohibited substance.


The Polyclinic Pharmacy procedure for dispensing a prohibited substance will be:

• The prescribing doctor and the athlete who is receiving the medicine must sign the prescription form to confirm that they are aware of the prohibited status of the medicine.

• The dispensing pharmacist must confirm with the prescribing doctor that the substance is prohibited and confirm that they wish to proceed to prescribe the substance.

• The pharmacist should sign the prescription to verify that they have informed the prescribing doctor and the athlete that the substance is prohibited.

• If a prohibited substance is prescribed for an athlete by a Baku 2015 doctor, additional verification should be made with the duty Polyclinic Manager, who should also sign the prescription.

• The dispensing pharmacist should label the dispensed medicine as ‘Prohibited’.

5. The EOC Needle PolicyThe Baku 2015 European Games are ‘needle-free’ for all participating athletes. Needles must not be used except by: (i) medically qualified practitioners for the clinically justified treatment of injury, illness or other medical conditions (for which a valid TUE may be required); or (ii) those requiring auto-injection therapy for an established medical condition with a valid TUE, e.g. for insulin dependent diabetes.

It is the responsibility of each athlete, his/her entourage and each NOC to ensure compliance with this Needle Policy. Each NOC must ensure that:

1. Any needles and associated clinical materials, intended for use by members of its delegation, are stored in a central secured location, access to which is restricted to authorized medical personnel of the NOC delegation. Athletes with a valid TUE for the use of insulin, and non-athletes requiring other forms


of auto-injection, may keep appropriate materials with them if safely stored and disposed of.

2. All used needles and associated materials (vials, syringes, and swabs) are safely disposed of in an appropriate bio-hazards container (e.g. sharps bin). If necessary, these may be obtained from the Polyclinic Pharmacy in the Athletes Village.

3. Whenever an Athlete receives an injection during the period of the Baku 2015 European Games (i.e. from the date of the opening of the Athletes Village on 8 June 2015 up to and including the date of the Closing Ceremony on 28 June 2015), the ‘Injection Declaration Form’ is duly completed and emailed to the EOC Medical and Anti-doping Commission at [email protected] or submitted via the deposit box at the Athletes Village Polyclinic Pharmacy no later than 12:00 the day following such injection. This applies to all injections administered to Athletes whether they occur in the Athletes Village, elsewhere in Azerbaijan, or in another country.

4. Injection Declaration Forms must be completed legibly in English and any additional evidence attesting to the need for injection therapy (e.g. imaging, laboratory reports), are attached.

No Injection Declaration Form is required if the injection has been administered in the Athletes Village Polyclinic by a medically qualified practitioner working with the Baku 2015 Medical Services and the injection has been recorded in the ATOS medical encounter system.

Acupuncture or the use of dry needling techniques are not considered to be a medical injection and thus an Injection Declaration Form is not required for these treatments.

Failure to respect this Needle Policy, including failure to submit a completed Injection Declaration Form to the EOC Medical and Anti-doping Commission, may expose the Athlete(s), the entourage of the Athlete(s), the NOC and members of its delegation as well as the person(s) having administered the injection to disciplinary action, additional testing and sanctions, as determined by the EOC Executive Board.



5.1 Medical justification of injections

There is no justification for any Athlete (except those with an established clinical condition requiring auto-injection and a valid TUE), a coach or any other non-medically qualified person to administer an injection.

Injections are only permitted when there is a clinically justified reason for such an intervention as determined by the EOC Medical and Anti-doping Commission. All completed Injection Declaration Forms will be reviewed by the EOC Medical and Anti-doping Commission. Any concerns identified as a result will prompt a review of the rationale and justification for the treatment by a panel of physicians convened by the EOC Medical and Anti-doping Commission. Ordinarily this review will include a meeting with the practitioner(s) involved in the administration of the injection.

If there is a dispute as to whether the medical justification of the injection is accepted as normal medical practice (as defined above), the issue may be referred to the EOC Executive Board by the Chairman of the EOC Medical and Anti-doping Commission.

If the relevant NOC or International Federation also has rules in place regarding the subject matter dealt with herein, the rules of the relevant NOC or International Federation shall also apply. In the event of any conflict between such rules and the present Policy, during the period of the Baku 2015 European Games, the EOC Executive Board shall resolve the discrepancy.

6. The Pharmacy Medicines ListThe medicines included in the Pharmacy Guide are listed in alphabetical order according to their generic name.

The following information is included:

• Drug name

• Dosage Form

• Status according to the World Anti-Doping Agency 2015 Prohibited List


The current full WADA 2015 Prohibited List can be found at www.wada-ama.org

6.1 Drug and Prescribing Information

Comprehensive information about drug dosing, side-effects, cautions and interactions, and other useful prescribing advice will be provided for all medical staff from the Athlete Village Pharmacy team.

Access to online medicines information will be available for all medical providers at the Games.

Please contact the Polyclinic Pharmacy in the Athlete Village for all medicines information queries and information about recommended medicines reference resources available.

www.wada-ama.org

Generic Name Dosage Form Strength Pack Size WADA statusAcetazolamide tablets 250mg 3x10 ProhibitedAcetylsalicylic acid tablets 300mg 2x10 PermittedAcetylsalicylic acid tablets 100mg 2x14 PermittedAciclovir tablets 200mg 1x10 PermittedAciclovir tablets 400mg 1x10 PermittedAciclovir cream, tube 50mg/g 5g PermittedAciclovir eye ointment, tube 5% 5g PermittedAluminium hydroxide, Magnesium hydroxide oral suspension 3.5g/4g/100ml 1x250ml PermittedAmiodarone injection, ampoule 50mg/ml 6x3ml PermittedAmiodarone tablets 200mg 3x10 Permitted

Amitriptyline tablets 10mg 5x10 PermittedAmitriptyline tablets 25mg 1x50 PermittedAmlodipine tablets 10mg 3x10 PermittedAmlodipine tablets 5mg 3x10 PermittedAmoxicillin capsules 250mg 1x10 PermittedAmoxicillin capsules 500mg 1x10 PermittedAmoxicillin, Clavulanic acid tablets 500mg/125mg 2x5 PermittedAmylmetacresol, Dichlorobenzyl alcohol lozenges 0.6mg/1.2mg 2x12 PermittedAqueous Cream 250ml PermittedArticaine hydrochloride, Epinephrine (adrenaline) hydrochloride

injection, ampoule 40mg/0.012mg/ml 10x1,7ml Permitted only for local administration

Ascorbic acid effervescent tablets 250mg 1x20 PermittedAtropine sulphate eye drops 10mg/ml 1x5ml Permitted

Generic Name Dosage Form Strength Pack Size WADA statusAtropine sulphate injection, ampoule 1mg/ml 10x1ml PermittedAzithromycin capsules 250mg 1x6 PermittedBeclomethasone dipropionate solution for inhalation 100mcg/dose 1x200dose PermittedBeclomethasone dipropionate solution for inhalation 50mcg/dose 1x200dose PermittedBenzoyl peroxide gel, tube 5% 40g PermittedBenzydamine hydrochloride oral rinse 0.15% 1x120ml PermittedBenzydamine hydrochloride oral spray 0.15% 1x120ml PermittedBenzylpenicillin injection, powder for

reconstitution1000000IU 1 vial Permitted

Betahistine tablets 8mg 1x30 PermittedBetamethasone injection, ampoule 7mg/ml 5x1ml Prohibited by

intramuscular and intravenous injection

Budesonide, Formoterol fumarate dihydrate dry powder inhaler 160mcg/4.5mcg/dose

1x60dose Formoterol is not prohibited up to a maximum of 54 micrograms over 24 hours

Bupivacaine injection, ampoule 0.50% 5x4ml PermittedCefotaxime sodium injection,powder for

reconstitution with solvent

1g 1 vial / 1 am-poule

Permitted

Ceftriaxone sodium injection,powder for reconstitution with solvent

1g 1 vial / 1 am-poule

Permitted

Generic Name Dosage Form Strength Pack Size WADA statusCelecoxib capsules 100mg 2x10 PermittedCelecoxib capsules 200mg 2x10 PermittedCetirizine tablets 10mg 3x10 PermittedChloramphenicol eye drops 0.25% 1x5ml PermittedChlorhexidine gluconate, Benzydamine hydrochlo-ride

oral rinse 0.12%/0.15% 1x200ml Permitted

Chloroquine tablets 250mg 3x10 PermittedChlorpromazine tablets 25mg 1x20 PermittedChlorpyramine tablets 25mg 2x10 PermittedChlorpyramine injection, ampoule 20mg/ml 5x1ml PermittedCholine salicylate ear drops 20% 1x10g Permitted

Ciprofloxacin tablets 250mg 1x10 PermittedCiprofloxacin tablets 500mg 1x10 PermittedCitric acid monohydrate oral solution 2.50% 1x200ml PermittedClarithromycin tablets 250mg 1x10 Permitted

Clobetasol propionate cream, tube 0.05% 25g PermittedClopidogrel tablets 75mg 2x14 PermittedClotrimazole cream, tube 10mg/g 20g PermittedClotrimazole vaginal tablets 100mg 1x6 PermittedCodeine phosphate, Paracetamol tablets 8mg/500mg 4x8 PermittedCodeine phosphate, Paracetamol tablets 30mg/500mg 10x10 PermittedColchicine tablets 1mg 2x30 PermittedCyclopentolate hydrochloride eye drops 1% 20x0.5ml Permitted

Generic Name Dosage Form Strength Pack Size WADA statusDexamethasone 1mg; Neomycin (as sulfate ) 3.5mg Polymyxin B – sulfate 6000IU

eye / ear drops 1mg/3.5mg/6000IU 1x5ml Permitted

Dextrose infusion 10% 1x500ml Prohibited as infusion of more than 50mL/6 hours

Dextrose infusion 5% 1x500ml Prohibited as infusion of more than 50mL/6 hours

Diazepam injection, ampoule 5mg/ml 5x2ml PermittedDiazepam tablets 5mg 1x20 PermittedDiclofenac gel, tube 1% 20g PermittedDiclofenac injection, ampoule 25mg/ml 5x3ml PermittedDiclofenac tablets 25mg 3x10 PermittedDiclofenac tablets 50mg 2x10 PermittedDiclofenac sodium eye drops 0.10% 1x5ml Permitted

Digoxin tablets 250mcg 2x15 PermittedDihydrocodeine tablets 30mg 1x100 PermittedDimetindene maleate gel, tube 1mg/g 30g PermittedDomperidone tablets 10mg 1x10 PermittedDoxycycline effervescent tablets 100mg 1x10 PermittedEpinephrine (adrenaline) injection, ampoule 1/1000 10x1ml Prohibited; but permitted

by local administration or co-administration with local anaesthetic agents

Erythromycin tablets 250mg 1x10 PermittedFlucloxacillin capsules 250mg 1x28 PermittedFluconazole capsules 150mg 1x1 Permitted

Generic Name Dosage Form Strength Pack Size WADA statusFluconazole capsules 50mg 1x7 PermittedFluorescein sodium eye drops 2% 20x0.5ml PermittedFluorometholone eye drops 0.10% 5ml PermittedFluticasone propionate aerosol inhalation 125mcg/dose 1x60dose PermittedFluticasone propionate nasal spray 50mcg/dose 1x120dose PermittedFluticasone propionate nasal spray 50mcg/dose 1x120dose PermittedFluticasone propionate, Salmeterol aerosol inhalation 125mcg/25mcg/

dose1x120dose Permitted by inhalation

only within manufacturer’s recommended therapeutic regimen

Furosemide injection, ampoule 10mg/ml 10x2ml ProhibitedFurosemide tablets 40mg 5x10 ProhibitedFusidic acid eye drops 1% 1x5g Permitted

Fusidic acid sodium salt ointment, tube 2% 15g PermittedGlucagon injection, powder for

reconstitution1mg 1x1 Permitted

Glucose oral gel, tube 10g 1x25g PermittedGlycerol suppository 2.11g 1x10 Permitted when used as

suppository in normal dose; prohibited as plasma expander

Hyaluronate sodium injection, prefilled syringe

10mg/ml 1x2ml Permitted

Hydrocortisone topical ointment, tube 0.4mg/dose 10gr PermittedHydrocortisone sodium succinate injection, powder for

reconstitution100mg 1x1 Prohibited by intramuscular

and intravenous injection

Generic Name Dosage Form Strength Pack Size WADA statusHypromellose eye drops 0.3% 1x15ml PermittedIbuprofen gel, tube 5% 50g PermittedIbuprofen tablets 200mg 1x12 PermittedIbuprofen tablets 400mg 1x12 PermittedInsulin aspart injection, pre-filled pen 100IU/ml 5x3ml ProhibitedInsulin bipashic aspart injection, pre-filled pen 100IU/ml 5x3ml ProhibitedInsulin glargine (rDNA) injection, pre-filled pen 100IU/ml 5x3ml ProhibitedInsulin human (rDNA) injection, vial 1000IU 10ml ProhibitedIpratropium bromide aerosol inhalation 20mcg/dose 1x200dose(10ml) PermittedIpratropium bromide nebuliser solution 0.25mg/ml 1x20ml Permitted

Iron (III) hydroxide polymaltose complex chewable tablets 100mg 3x10 PermittedKetamine injection, vial 50mg/ml 5x10ml PermittedKetoprofen gel, tube 2.50% 50g PermittedLactulose syrup 667mg/ml 1x200ml PermittedLevonorgestrel tablets 1.5mg 1x1 PermittedLidocaine injection, ampoule 20mg/ml 10x2ml PermittedLidocaine hydrochloride, Chlorhexidine dihydro-chloride

tube gel for catheter 2g/0.05g 1x12.5g Permitted

Lidocaine hydrochloride, Epinephrine (adrena-line) hydrochloride

injection, ampoule 20mg/0,0125mg/ml

10x2ml Permitted only by local administration

Lidocaine, Prilocaine cream, tube 25mg/25mg/g 5x5g PermittedLoperamide capsules 2mg/ml 1x 20 PermittedLoratadine tablets 10mg 2x10 Permitted

Generic Name Dosage Form Strength Pack Size WADA statusLubricant, personal gel - 3x5ml PermittedMebeverine hydrochloride tablets 135mg 3x10 PermittedMethylprednisolone injection, powder for

reconstitution250mg 1 vial Prohibited by


Metoclopramide tablets 10mg 1x50 PermittedMetoclopramide injection, ampoule 5mg/ml 10x2ml PermittedMetronidazole tablets 250mg 2x10 PermittedMetronidazole tablets 500mg 1x20 PermittedMiconazole nitrate oral gel, tube 2% 40gr PermittedMiconazole nitrate cream, tube 2% 30gr PermittedMidazolam injection, ampoule 5mg/ml 5x3ml Permitted

Mupirocin ointment, tube 2% 15g PermittedNaloxone injection, ampoule 0.4mg/ml 10x1ml PermittedNaproxen tablets 275mg 1x10 PermittedNifedipine tablets 10mg 1x50 PermittedNitroglycerin aerosol 0.4mg/dose 1x180dose PermittedNorethisterone tablets 5mg 2x10 PermittedNystatin oral suspension 100000IU/ml 1x48dose PermittedOfloxacin tablets 200mg 1x10 PermittedOfloxacin eye drops 3mg/g 1x5ml PermittedOlopatadine eye drops 0.10% 5ml PermittedOmeprazole capsules 20mg 3x10 Permitted

Generic Name Dosage Form Strength Pack Size WADA statusOndansetron injection, ampoule 2mg/ml 5x2ml PermittedOral rehydration salt oral powder, sachet 18.9g 1x20 PermittedParacetamol oral suspension 120mg/5ml 1x100ml PermittedParacetamol soluble tablets 500mg 4x4 PermittedParacetamol tablets 500mg 1x12 PermittedPenicillin V tablets 250mg 1x10 PermittedPermethrin solution 5mg/g 1x60ml PermittedPhenylephrine hydrochloride eye drops 10% 20x0.5ml PermittedPhenylephrine hydrochloride eye drops 2.50% 1x5ml PermittedPholcodine oral solution 0.10% 1x200ml Permitted

Pilocarpine eye drops 1% 1x5ml PermittedPolymyxin B sulphate 10000IU, Neomycin sulphate 5mg, Hydrocortisone acetate 10mg, Lidocaine 30mg

ear drops 10000IU/5mg/10mg/30mg 1x10ml Permitted

Potassium carbonate, Magnesium carbonate (ant-acid)

chewable tablets 680mg/80mg 2x12 Permitted

Potassium chloride, Potassium bicarbonate effervescent tablets 470mg 10x10 PermittedPotassium citrate oral powder, sachet 3g 1x60 PermittedPovidone-iodine solution 100mg/ml 1x120ml PermittedPrednisolone tablets 5mg 1x100 ProhibitedPrednisolone eye drops 1% 1x5ml PermittedProparacaine hydrochloride eye drops 0.50% 1x15ml PermittedPropranolol tablets 40mg 1x100 Prohibited in

archery and shooting events

Generic Name Dosage Form Strength Pack Size WADA statusPropranolol tablets 10mg 5x20 Prohibited in archery

and shooting eventsRanitidine hydrochloride tablets 150mg 2x10 PermittedRocuronium bromide injection, multi dose

vials10mg/ml 5x10ml Permitted

Salbutamol aerosol inhalation 100mcg/dose 1x200dose Permitted by inhalation within normal dose regimen (maximum 1600 mcg over 24 hours)

Senna extract tablets 13.5mg 1x20 PermittedSimeticone oral drops 40mg/ml 1x30ml PermittedSodium alginate 500mg/10ml, Sodium hydro-carbonate 267mg/10ml, Calcium carbonate 160mg/10ml

oral suspension 500mg/267mg/160mg/10ml 1x300ml Permitted

Sodium chloride injection, ampoule 0.90% 10x10ml PermittedSodium chloride infusion 0.90% 500ml IV infusion of more

than 50ml/6hours is a prohibited method unless it is received during an hospital administration or a clinical investigation

Sodium chloride nasal drops - 1x10ml Permitted

Sodium chloride irrigation solution, sachets

0.90% 25x25ml Permitted

Sodium cromoglicate eye drops 4% 1x5ml Permitted

Generic Name Dosage Form Strength Pack Size WADA statusSpacer pcs - 1x1 PermittedSudocream cream, jar - 60g PermittedSulfadiazine silver salt cream, tube 1% 50g PermittedSulfamethoxazole, Trimethoprim tablets 400mg/80mg 2x10 PermittedSumatriptan tablets 50mg 1x6 PermittedTerbinafine cream, tube 1% 15g PermittedTerbinafine spray 1% 1x30g PermittedTerbutaline Turbohaler powder inhalation 0.5mg/dose 1x200dose ProhibitedTetracycline hydrochloride eye ointment, tube 1% 3g PermittedTobramycin eye ointment, tube 0.30% 3.5g Permitted

Topical skin adhesive topical skin adhesive, plastic ampoule

0.5g 10x0.5g Permitted

Tramadol tablets 50mg 2x10 PermittedTramadol injection, ampoule 50mg/ml 5x2ml PermittedTranexamic acid tablets 500mg 5x12 PermittedTriamcinolone injection, ampoule 40mg/ml 5x1ml Prohibited by


Tribenoside, Lidocaine hydrochloride rectal cream, tube 50mg/20mg/g 1x30g PermittedTropicamide eye drops 0.50% 1x15ml PermittedWarfarin tablets 3mg 1x30 PermittedWarfarin tablets 5mg 1x30 PermittedWater for injection injection, ampoule - 10x5ml Permitted

Generic Name Dosage Form Strength Pack Size WADA statusWhite soft paraffin (Vaseline) gel, jar - 1x30g PermittedXylometazoline hydrochloride nasal drops 0.10% 1x10ml PermittedXylometazoline hydrochloride nasal spray 0.10% 1x15ml PermittedZopiclone tablets 7.5mg 1x20 Permitted

Baku 2015 would like to thank the following companies and organisations for their support.

Official Partners

Official Supporters

Official Child’s Rights Organisation

Baku 2015 European Games Operations Committee. 41 Zarifa Aliyeva Street, Baku, AZ1000, Azerbaijanbaku2015.com

baku2015.com

Baku 2015 medical anti doing and pharmacy guide

Documents

Transcript of Baku 2015 medical anti doing and pharmacy guide